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Epidemiologi ved gastroøsofageal refluks 
 
Gastroøsofageal refluks er tilbakestrøm av mageinnhold til spiserøret. 
Hovedsymptomene ved refluks er halsbrann og sure oppstøt. Refluks kan gi skader på 
slimhinnen i spiserøret og redusert livskvalitet. Hos noen få kan refluks også bidra til 
utvikling av kreft i spiserøret. I Helseundersøkelsen i Nord-Trøndelag (HUNT) 
rapporterte 60 000 voksne deltakere i HUNT 2 (1995-1997) og 45 000 voksne 
deltakere i HUNT 3 (2006-2009) sine plager med halsbrann og sure oppstøt. Blant 
disse deltok 30 000 individer både i HUNT 2 og HUNT 3. 
Gastroøsofageal reflukssykdom, definert som minst ukentlige plager med 
reflukssymptomer, er hyppig og økende i befolkningen. I tidsrommet mellom HUNT 
2 og HUNT 3 økte andelen som anga minst ukentlige reflukssymptomer med 47 %, 
fra 11,6 % til 17,1 % av befolkningen. Symptomene økte for begge kjønn og i alle 
aldersgrupper fra 20-års alder. I gjennomsnitt oppstod nye, alvorlige 
reflukssymptomer årlig hos 0,23 % av befolkningen i denne perioden.  I samme 
periode ble i gjennomsnitt 1,22 % kvitt alvorlige reflukssymptomer årlig uten bruk av 
medisiner. De yngste ble hyppigere kvitt plagene sine enn de eldste. 
Overvekt og tobakksrøyking er kjente risikofaktor for reflukssykdom, men det har 
vært uklart om vektnedgang eller røykekutt bedrer sykdommen. Dette ble undersøkt 
blant individene som deltok i både HUNT 2 og HUNT 3. Individene som gikk ned i 
vekt mellom HUNT 2 og HUNT 3 hadde større sjanse for bedring av 
reflukssymptomene enn individene som hadde stabil vekt eller gikk opp i vekt. 
Individene med størst vektnedgang hadde større sjanse for bedring av plagene enn 
individene med mindre vektnedgang. De som hadde gått ned i vekt hadde også større 
sjansen for vellykket behandling med medisiner. Individene som kuttet ut 
dagligrøyking mellom HUNT 2 og HUNT 3 hadde også økt sjanse for bedring av 
alvorlige reflukssymptomer sammenlignet med de som fortsatte å røyke daglig. 
Røykekutt bedret bare symptomene hos normalvektige som brukte medisiner 
regelmessig mot plagene. Dette skyldes trolig at overvekt er en sterkere risikofaktor 
for reflukssykdom enn røyking, og at det hos overvektige ikke er nok å kutte ut 
røyken for å bedres. 
Studien viser derfor at vektnedgang og røykekutt kan være gunstig for å forebygge og 
behandle reflukssykdom, og at individer som ikke har tilfredsstillende effekt av 
medikamentell behandling mot reflukssykdom kan ha nytte av vektnedgang og 
røykekutt. 
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Summary 
 
Introduction 
Heartburn and acid regurgitation are the characteristic gastro-oesophageal reflux 
symptoms (GORS). GORS are associated with reduced quality of life and increased risk 
of oesophageal adenocarcinoma. GORS are highly prevalent in Western populations, 
but the changes in prevalence, incidence, and loss of GORS over time are unsettled. 
Overweight and tobacco smoking are known risk factors of GORS. However, whether 
weight loss or tobacco smoking cessation improves GORS is unclear. The aims of this 
thesis were to address changes in the occurrence of GORS in the same population over 
time and the associations between weight loss and tobacco smoking cessation and 
improvement in GORS. 
 
Materials and methods 
The thesis is based on data from the Nord-Trøndelag Health Study (HUNT), a series of 
population-based health surveys conducted in Nord-Trøndelag County, Norway. In 
HUNT 2 (1995 to 1997) and HUNT 3 (2006 to 2009) all adult residents of the county 
were invited. The participants received questionnaires on several health related topics, 
including complaints with GORS, and clinical measurements were performed at 
examination sites. In addition, data on antireflux medication was collected through the 
Norwegian Prescription Database. The prevalence of any, severe, and at least weekly 
GORS during HUNT 2 and HUNT 3 and the cumulative incidence and loss of GORS 
10  
between HUNT 2 and HUNT 3 were calculated. The association between weight loss 
and GORS and between tobacco smoking cessation and GORS was assessed by 
multivariable logistic regression, providing odds ratios (OR) and 95% confidence 
intervals (CI), while taking potential confounding factors into consideration. 
 
Results 
In HUNT 2 and HUNT 3, 58 869 and 44 997 participants answered the GORS 
questionnaire, respectively. This corresponded to response rates of 64% and 49%, 
respectively. Of the HUNT 2 participants, 29 610 individuals were prospectively 
followed up at HUNT 3, corresponding to a response rate of 61%. During the average 
11-year period between 1995 to 1997 and 2006 to 2009, the prevalence of any, severe, 
and at least weekly GORS increased by 30% (from 31.4% to 40.9%), 24% (from 5.4% 
to 6.7%), and 47% (from 11.6% to 17.1%), respectively. The average annual incidence 
of any and severe GORS was 3.07% and 0.23%, respectively. In women, but not men, 
the incidence of GORS increased with increasing age. The average annual spontaneous 
loss (not due to antireflux medication) of any and severe GORS was 2.32% and 1.22%, 
respectively. The spontaneous loss of GORS decreased with increasing age. Weight loss 
was dose-dependently associated with reduction of GORS and an increased treatment 
success with antireflux medication. Among individuals with >3.5 units decrease in body 
mass index (BMI), the OR of loss of any (minor or severe) GORS was 1.98 (95% CI 
1.45 to 2.72) when using no or less than weekly antireflux medication, and 3.95 (95% 
CI 2.03 to 7.65) when using at least weekly antireflux medication. The corresponding 
ORs of loss of severe GORS was 0.90 (95% CI 0.32 to 2.55) and 3.11 (95% CI 1.13 to 
11 
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8.58). Among individuals using less than weekly antireflux medication, there was no 
association between tobacco smoking cessation and improvement in GORS (OR 0.95, 
95% CI 0.39 to 2.30). However, when antireflux medication was used at least weekly, 
cessation of daily tobacco smoking was associated with improvement in GORS from 
severe to no or minor complaints (OR 1.78, 95% CI 1.07 to 2.97), compared with 
persistent daily smoking. This association was present among individuals within the 
normal range of BMI (OR 5.67, 95% CI 1.36 to 23.64), but not among overweight 
individuals. 
 
Conclusions 
Between 1995 to 1997 and 2006 to 2009 the prevalence of GORS increased 
substantially. At least weekly GORS increased by 47%. The average annual incidence 
of severe GORS was 0.23%, and the corresponding spontaneous loss was 1.22%. The 
incidence and spontaneous loss of GORS were influenced by sex and age. Weight loss 
was dose-dependently associated with both a reduction of GORS and an increased 
treatment success with antireflux medication. Tobacco smoking cessation was 
associated with improvement in severe GORS in individuals of normal BMI using at 
least weekly antireflux medication.
12  
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1 Introduction 
 
1.1 Gastro-oesophageal reflux 
 
1.1.1 Definitions 
Gastro-oesophageal reflux means backflow of stomach content to the oesophagus. 
Heartburn, a burning retrosternal sensation, and acid regurgitation, the perception of 
flow of stomach content into the mouth or hypopharynx, are the characteristic gastro-
oesophageal reflux symptoms (GORS).(1) Other clinical presentations are also 
associated with gastro-oesophageal reflux disease (GORD), including epigastric and 
retrosternal pain, dysphagia (difficulty swallowing) and odynophagia (pain with 
swallowing), water brash (excessive salivation with reflux episodes), nausea, 
inflammation of the airways with related symptoms, and dental erosions. GORD is 
through “The Montreal definition and classification of GERD: A global evidence-based 
consensus” defined as “a condition which develops when the reflux of stomach contents 
causes troublesome symptoms and/or complications.”(2) The definition further states 
that “In population-based studies, mild symptoms occurring 2 or more days a week, or 
moderate/severe symptoms occurring more than 1 day a week, are often considered 
troublesome by patients”. A modified Delphi process was used to develop this 
definition, using four principal steps: 1) selection of group members and drafting of 
statements; 2) systematic literature reviews for each statement; 3) grading of the 
collected evidence; and 4) discussion and repeated anonymous voting on a series of 
14 
iterations of the statements until a consensus was reached. Traditionally, the diagnosis 
of GORD has been made on the grounds of morphological changes of the oesophageal 
mucosa and on 24-hour pH-measurements of the distal oesophagus. The Montreal 
definition allow both asymptomatic individuals with demonstrated reflux complications 
and individuals with typical symptoms alone, without further investigations, to be 
defined as GORD patients, thus resulting in higher sensitivity in assessing GORD. 
 
1.1.2 Occurrence 
Prevalence is a measure of an existing state and may be defined as the proportion of 
individuals with a given disease in a population at a specified point in time. Incidence is 
a measure of new events or new cases of a given disease in a population during a 
defined period of time. Incidence may be reported as a cumulative incidence, which is 
the proportion of the population that get a disease during a given period of time. 
Cumulative incidence is sometimes also called incidence risk or incidence 
proportion.(3) 
GORD, defined as at least weekly GORS, is highly prevalent in Western populations. In 
Western Europe, North America, Australia, and New Zealand the prevalence of GORD 
is reported to be between 9% and 25%, with a higher prevalence in more recent 
studies.(4-11) However, in other parts of the world the prevalence is generally lower. In 
Asia, the prevalence is reported to be between 2% and 10% (12-14) and in Sub-Sahara 
Africa the disease is rare.(14, 15) The incidence of GORD defined as at least weekly 
GORS, has previously only been addressed in one population-based study of 690 
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participants from the United States. After 12-20 months follow-up from 1988 to 1991 
the cumulative incidence was reported to be 2.7%.(16) 
 
1.1.3 Pathophysiology 
There are four main factors involved in the pathophysiology of GORD: 1) the antireflux 
barrier; 2) the composition of the refluxed material; 3) the clearance of the refluxed 
material; and 4) the oesophageal mucosal resistance. 
 
1) The antireflux barrier 
At the oesophagogastric junction between the oesophagus and stomach there is an 
antireflux barrier which consists of the internal muscle layers of the distal oesophagus 
and proximal stomach (internal part) and the diaphragm and its supporting connective 
tissue (external part).(17) The smooth muscles in a 3 to 4 cm long segment of the distal 
oesophagus are tonically contracted creating a lower oesophageal sphincter (LOS).(18) 
The oblique muscle fibres of the proximal stomach create a narrow angle (the angle of 
His) where the oesophagus enters the stomach and act as a flap valve mechanism.(19) 
The crural part of the diaphragm forms the opening (hiatus) through which the 
oesophagus enters the abdomen and contraction of the diaphragm exerts a pinchcock-
like action on the oesophagus.(20) 
There are three main mechanisms which compromise the antireflux barrier: a) transient 
lower oesophageal sphincter relaxations (TLOSRs); b) hypotensive LOS; and c) 
anatomic disruption of the barrier.(17) 
16 
 
a) TLOSRs 
TLOSRs are relaxations of the LOS and the crural diaphragm not triggered by 
swallowing.(21) This is a physiological mechanism which allows us to belch.(22, 23) 
The TLOSRs are also the most common mechanism of reflux, both in normal 
individuals and in GORD patients.(24, 25) TLOSRs are responsible for the majority of 
acid reflux episodes, but the rate of TLOSRs is similar in healthy individuals and 
GORD patients. However, the TLOSRs are more likely to be associated with reflux 
episodes in GORD patients.(26, 27) In GORD patients, an increased pressure gradient 
over the oesophagogastric junction and an increased compliance of the junction 
compared with healthy individuals facilitates reflux.(28, 29) As GORD becomes more 
severe the other mechanisms compromising the antireflux barrier become more 
important.(30) 
 
b) Hypotensive LOS 
The LOS has normally a resting pressure of 10 to 30 mmHg compared with the 
intragastric pressure and relaxes at the initiation of swallowing to allow passage of 
food.(18) Hypotensive LOS is present in a minority of GORD patients.(31) Reflux 
occurs when the hypotensive LOS pressure is overcome by an abrupt increase in the 
intraabdominal pressure (strain-induced reflux) or by free reflux if the LOS pressure is 
very low (0 to 4 mmHg).(25, 32) In addition, the LOS pressure can be reduced by 
various foods, including fat,(33) chocolate,(34) caffeine,(35) and alcohol(36). 
Hormones,(37) including elevated progesterone levels during pregnancy,(38, 39) and 
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drugs, including nitrates and dihydropyridine calcium channel antagonists,(40) beta-
agonists,(41) anticholinergic drugs,(42) and benzodiazepines,(43) are also known to 
reduce the LOS pressure. 
 
c) Anatomic disruption of the barrier 
Hiatal hernia is a condition where a portion of the stomach is pulled up through the 
diaphragm and into the thoracic cavity. This counteracts the flap valve mechanism of 
the angle of His.(44) In addition, such hernia impairs clearance of acid from the 
oesophagus by trapping acid in the hernia sac, which subsequently is re-refluxed with 
the next swallow-induced relaxations of the LOS.(45, 46) A large hernia impairs the 
pinchcock-like action of the diaphragm on the distal oesophagus.(47) The majority of 
patients with moderate to severe GORD have hiatal hernia and the severity of 
oesophagitis correlates with hernia size.(17, 48) Hiatal hernia is associated with an 
increased frequency of TLOSRs.(49) However, TLOSRs play a less important role in 
the occurrence of reflux than in GORD patients without hiatal hernia.(50) 
 
2) The composition of the refluxed material 
It is mainly the acid of the stomach content that can cause damage to the oesophageal 
mucosa. The proton (H+) diffuses into the mucosa, leading to cellular acidification and 
necrosis.(51) In addition pepsin, bile acids, trypsin, and food hyperosmolality increase 
the susceptibility of the mucosa to acid injury.(52) The level of acidity and the length of 
the reflux episodes define the degree of damage.(53) In GORD, a pH < 4 in > 4% of the 
18 
time during a 24-hour pH-measurement is considered pathological.(54) The enzymatic 
activity of pepsin is pH dependent and pepsin is activated in an acidic environment. 
Non-acid reflux can also cause symptoms and appears in part to be responsible for 
persistent symptoms despite medical treatment.(55) 
 
3) The clearance of the refluxed material  
The oesophagus is cleared of acid content by gravity and peristalsis moving down the 
oesophagus into the stomach.(24) In addition, residual acid is neutralised by swallowed 
saliva.(56) Peristaltic dysfunction compromises oesophageal acid clearance and occurs 
in a substantial minority of GORD patients.(31) Delayed gastric emptying is also 
associated with prolonged acid contact time in the oesophagus by triggering 
TLOSRs.(57) Chronic xerostomia (dry mouth) is also associated with reduced clearance 
of acid and oesophageal injury.(58) In addition, hiatal hernias impair the oesophageal 
clearance by trapping of acid content in the hernia sac and re-reflux, as explained above. 
Head of bed elevation has been shown to improve acid clearance from the 
oesophagus.(59) 
 
4) The oesophageal mucosal resistance 
The oesophageal mucosal resistance consists of preepithelial, epithelial, and 
postepithelial defences.(60) The preepithelial defences of surface mucous and 
bicarbonate, which maintain a pH gradient between lumen and cell surface, are poorly 
developed in the oesophagus.(61) The main defence is the epithelia itself, because of 
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tight junctions and a lipid rich matrix in the intercellular spaces.(62) The main 
postepithelial defence is blood flow, which provides bicarbonate to the extracellular 
space where protons extruded by pH-activated pumps on the oesophageal membranes 
are buffered.(51) 
  
1.1.4 Aetiology 
In contrast to pathophysiology, which is the study of disease mechanisms, aetiology is 
the study of what causes disease. Pathophysiology is typically studied by laboratory 
methods on patients, volunteers, or laboratory animals, while aetiology is studied by 
epidemiological methods to identify risk factors and subsequently causal relations. 
There is an increased risk of GORS within families (63) and a higher concordance in 
prevalence of GORS in monozygotic over dizygotic twin pairs,(64) suggesting a genetic 
influence. A few lifestyle-related factors have in population-based studies been 
associated with an increased risk of GORS, mainly high body mass index (BMI) (6, 8, 
63, 65-72) and tobacco smoking.(6, 10, 63, 69, 73) High dietary fibre intake and 
moderate physical exercise seem to protect against GORS.(69, 73)  Low socioeconomic 
status and education has also been associated with an increased risk of GORS.(8, 74) 
Some studies also find an increasing risk of GORS with increasing age (5, 6, 66, 75) 
and for men.(70, 76) In pregnancy, physiological responses increase the amount of 
GORS. Hormonal changes during pregnancy reduce the LOS resting pressure(77) and 
the mechanical pressure against the LOS barrier in the later stages of the pregnancy is 
increased, both favouring reflux events. In addition, hormone replacement therapy is 
also associated with GORS, probably by reducing the LOS resting pressure.(67, 78) 
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1.1.5 Complications 
The Montreal definition and classification recognises several complications of gastro-
oesophageal reflux which is divided into different syndromes (figure 1).(2) 
 
 
 
 
 
 
 
 
 
Figure 1 The overall definition of GORD and its constituent syndromes(2) 
 
The complications are either oesophageal or extra-oesophageal. The extra-oesophageal 
syndromes are further divided into syndromes with established associations with GORD 
and conditions with proposed associations with GORD. Chronic cough, laryngitis, 
asthma, and dental erosions are associated with GORD, but the syndromes are usually 
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multifactorial where reflux rarely is the sole cause.(2) Whether reflux is a causal or 
exacerbation factor in pharyngitis, sinusitis, idiopathic pulmonary fibrosis, or recurrent 
otitis media is unclear.(2) The oesophageal syndromes are further divided into 
symptomatic syndromes and syndromes with oesophageal injury. The symptomatic 
syndromes are constellations of symptoms and further tests are not necessary to 
establish the diagnosis. Minor symptoms that occur for two or more days a week, or 
moderate to severe symptoms that occur for more than one day a week, reduces health-
related quality of life.(79, 80) In addition, GORS has a considerable impact on work 
productivity.(81) The syndromes with oesophageal injury require further diagnostic 
testing to be established, i.e. by upper endoscopy. Upper endoscopy is a visualisation of 
the mucosa of the upper gastrointestinal tract done by passing a tube with optical 
lightning and camera through the mouth. The upper endoscopy provides objective signs 
of reflux complications. Oesophagitis, defined as endoscopically visible breaks of the 
distal oesophageal mucosa, is the most common consequence of oesophageal injury. 
Today, oesophagitis is most frequently assesses by the Los Angeles classification.(82, 
83) However, oesophagitis was only seen in 29% of participants with weekly GORS in 
a Swedish survey (the Kalixanda study).(84) These patients might have non-erosive 
reflux disease (NERD) with pathological acid exposure on 24-hour pH-measurements 
of the distal oesophagus. Whether NERD and erosive reflux disease are distinct entities 
or just represent a continuum of the same disease is debated.(60, 85) A less common 
complication of reflux is formation of strictures, which narrows the lumen of the 
oesophagus and might induce dysphagia, i.e. difficulty swallowing. In a study with 7-
year follow-up of patients with GORS, 0.08% and 1.9% developed strictures after a 
normal and erosive index upper endoscopy, respectively.(86) Peptic strictures are 
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usually readily and successfully treated with endoscopic dilatation. More severe 
complications of reflux are Barrett’s oesophagus (BO) and oesophageal 
adenocarcinoma (OAC). BO is the replacement of the normal squamous epithelia of the 
oesophagus with intestinal-type (columnar) epithelium due to oesophageal injury. In the 
Kalixanda study, BO was found in 1.6% of the general population and in 2.3% of those 
reporting GORS during the past 3 months.(87) In the 7-year follow-up study, none with 
a normal index upper endoscopy developed BO.(86) However, another study found that 
1.4% with low-grade oesophagitis (Los Angeles grade A and B) and 5.8% with high-
grade oesophagitis (Los Angeles grade C and D) had BO at 2-years follow-up.(88) BO 
is a premalignant condition, which may develop to OAC in about 0.1 to 0.2% per year 
overall.(89, 90) The risk is higher in long-segment BO or in BO with high grade 
dysplasia. OAC is a highly malignant disease with poor prognosis. The overall 5-year 
survival in patients with invasive oesophageal carcinoma is about 15 to 25%.(91) GORS 
are strongly associated with OAC.(92, 93) In some patients with typical GORS, 
pathological reflux has not been found either by upper endoscopy or by pH-
measurements. The cause of symptoms in these patients are not clear, but may be 
related to increased sensitivity to normal acid exposure or other stimuli (oesophageal 
hypersensitivity).(94, 95) 
 
1.1.6 Management 
There are three main approaches to the management of GORD: 1) lifestyle 
modification, 2) medical therapy, and 3) surgery. 
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1) Lifestyle modification 
As described above, a few lifestyle-related factors have a documented role in the 
pathophysiology of GORD and are associated with GORS in population-based studies. 
The lifestyle modifications broadly fall into 3 categories: a) avoidance of foods that may 
precipitate reflux (including coffee, alcohol, chocolate, and peppermint); b) avoidance 
of foods that can precipitate heartburn (including citrus, carbonated drinks, and spicy 
foods); and c) adoptions of behaviours that may reduce oesophageal acid exposure 
(including weight loss, smoking cessation, avoiding large meals, head of bed elevation, 
and avoiding recumbence after meals or meals before bedtime).(96, 97) If high-fat 
meals should be avoided is unclear. A controlled study did not find any change in LOS 
pressure or pH-measurements when comparing a low-fat and high-fat diet.(98) In a 
review of the evidence supporting lifestyle measures, only weight loss and head of bed 
elevation were found to be effective interventions for GORD. Both interventions 
improved pH profiles and weight loss also improved symptoms.(99) Head of bed 
elevation allows gravity to help clear the oesophagus of stomach content. A randomised 
controlled trail found effect on the healing of moderate oesophagitis and GORS by 20 
cm elevation of the head of the bed.(100) However, the evidence supporting the effect 
of weight loss and head of bed elevation is from small studies of highly selected patients 
only. No evidence supported improvement in GORD by cessation of tobacco smoking 
or alcohol consumption or other dietary interventions in the review.(99) This is mainly 
due to lack of studies assessing these interventions. Anyhow, treatment is aimed at the 
individual patient and management is based on that individual’s dietary intolerance or 
lifestyle, so avoiding exacerbating factors identified by the patient can be helpful. 
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2) Medical therapy 
Medical therapy is aimed at reducing the acidity of the refluxate or to improve clearance 
of the refluxed content. Treatment is guided by the severity of symptoms and 
complications, as well as the effectiveness of the initial therapy. With mild and 
infrequent symptoms without signs of complications, lifestyle modifications and 
antacids on demand are the main approaches. Antacids relieve symptoms by 
neutralising the acid and are effective and rapidly acting.(97) Sucralphate and alginate 
which are cytoprotective and coats the mucosa are also used for mild GORS. With more 
severe and frequent symptoms or complications, H2-reseptor antagonists (H2RAs) and 
proton pump inhibitors (PPIs) are usually preferred. The goal is then preventing 
symptoms and if oesophagitis, healing of the mucosa. In the long term (26 to 52 weeks) 
PPI therapy reduces the risk of relapsing erosive disease and symptoms better than 
H2RA, which in turn is better than placebo.(101-103) With severe oesophagitis (Los 
Angeles grades C or D), PPIs are the preferred medical treatment and long term use is 
usually needed to prevent recurrence of erosive disease.(103) The role of maintenance 
therapy in non-erosive disease or in GORD patients were endoscopy has not been 
conducted is less clear.(97) However, H2RAs are usually preferred over PPIs and at the 
lowest effective dosage. With strictures or BO, PPIs are generally preferred for an 
indefinite time, but it has not been shown that this reduces the incidence of OAC in 
BO.(97) So, medical therapy may last for an indefinite period of time, and the costs of 
these treatments are huge.(104, 105) In addition, long term and potent acid inhibition 
with PPIs can induce secondary hypergastrinemia which is associated with rebound 
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hypersecretion of acid (106) and PPIs have been shown to produce GORS in healthy 
volunteers after withdrawal.(107)  Moreover, low acid level in the stomach due to long 
term acid inhibition is associated with pneumonia,(108) Clostridium difficile 
infections,(109), reduced absorption of vitamin B-12,(110) and hypomagnesaemia.(111) 
The risk of hip fractures is also increased among long term users of PPIs, probably due 
to malabsorption of calcium.(112) 
In addition to acid inhibition, medical therapy aimed at the other pathophysiological 
aspects of GERD is available as adjunctive therapy. Metoclopramide, a dopamine 
receptor antagonist which increases the oesophagogastric motility, is a potential drug 
against GERD. However, frequent central nervous side effects make regular use 
inappropriate.(113) As TLOSRs have been shown to be important in the 
pathophysiology of GORD, neurotransmitters and receptors involved in the regulation 
of TLOSRs are potentially new targets for pharmacological treatment of GORD 
patients.(27) This includes drugs that reduce the rate of TLOSRs, as gamma-
aminobutyric acid receptor B (GABA-B) agonists (baclofen),(114) metabotropic 
glutamate receptor 5 (mGluR5) antagonists,(115) and cannabinoid receptor 1 (CBR1) 
agonists.(116) These drugs might be particularly useful in patient with refractory GORS 
on PPI therapy, because they can reduce symptoms due to non-acid reflux. However, 
central nervous system side effects are currently limiting the use of baclofen and data on 
side effects of the other drugs are needed.(27) 
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3) Surgery 
The indications for antireflux surgery are controversial. Surgery focuses on repairing the 
reflux barrier and controlling both acid and non-acid reflux.(117) It is believed that 
three mechanisms may play a role with antireflux surgery: 1) anatomical restoration of 
the oesophagogastric junction if a hiatal hernia is present, 2) decreased distensibility of 
the oesophagogastric junction,(118) and 3) a decreased rate of TLOSRs and decreased 
reflux associated with TLOSRs.(119) Both open and laparoscopic fundoplication are as 
effective as medical treatment with PPIs in preventing recurrence of oesophagitis and 
resolving of heartburn, but better on controlling acid regurgitation.(120, 121) On the 
other hand, surgically treated patients have higher rates of dysphagia, bloating, and 
flatulence.(120, 121) Surgery has not been shown to reduce the incidence of OAC in 
GORD patients (122) or BO patients.(123) So, if patients are judged to have similar 
effect of surgery and PPI therapy, the latter should be recommended as initial therapy 
because of superior safety. However, if the patient is responsive to, but intolerant of, 
acid suppressive therapy, surgery should be recommended as an alternative. In addition, 
patients with persistent troublesome regurgitation, despite PPI therapy, could benefit 
from surgery.(97) The potential benefits of surgery must, however, be weighed against 
the deleterious effects of surgery. Although the perioperative (124) and long-term (120, 
121) morbidity and mortality is generally low with laparoscopic fundoplication, the 
otherwise low morbidity and mortality with GORD demands therapies to be very safe. 
Moreover, many surgical patients need medical therapy in the long run postoperatively 
and surgical revision is common. Nevertheless, most adult patients (92%) are satisfied 
with the result of laparoscopic fundoplication.(125) Traditionally, best results have been 
found in patients with typical symptoms, good response to medication, pathological pH 
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measurements, and no motility disturbances.(126) However, a systematic review 
concluded that there was no consistent association between surgical outcome and 
preoperative characteristics.(127) 
 
1.2 Obesity and gastro-oesophageal reflux 
 
1.2.1 Definitions 
BMI is defined as the body weight in kilograms divided by the square height in metres 
(kg/m2). BMI is used in the World Health Organization’s International Classification of 
adult underweight, overweight and obesity: <18.50 is defined as underweight, 18.50 to 
24.99 as normal range, ≥25.00 as overweight, and ≥30.00 as obese.(128) 
 
1.2.2 Associations 
There is good evidence that overweight is associated with GORS. (6, 8, 63, 65-72) The 
relation between weight and GORS seems to be dose-dependent.(67, 129) The risk of 
GORS has even been shown to be higher in individuals with BMI in the upper normal 
range (22.5 to 24.9) compared to individuals with BMI in the lower normal range (20.0 
to 22.4). In the same study, BMI of less than 20.0 was also associated with a reduced 
risk of GORS compared to individuals with BMI in the lower normal range.(129) 
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1.2.3 Pathophysiology 
BMI and waist circumference are correlated with increased intragastric pressure and 
increased gastro-oesophageal pressure gradient that might lead to hiatal hernia.(130) 
Increasing BMI is correlated with increasing episodes of gastro-oesophageal reflux and 
higher acid exposure of the oesophagus.(131) Waist circumference may mediate a large 
part of the effect of obesity on oesophageal acid exposure.(132) Obesity is associated 
with an increased rate of TLOSRs, increased association of TLOSRs with reflux 
episodes, and increased pressure gradient over the oesophagogastric junction.(133) In 
addition, increasing BMI is correlated with higher volume and more proximal extent of 
reflux.(134) As higher acid exposure, volume, and proximal extent are associated with 
increased perception of GORS, obese individuals are also more likely to report 
symptoms.(135) 
 
1.3 Tobacco smoking and gastro-oesophageal reflux 
 
1.3.1 Associations 
Tobacco smoking is associated with GORS.(6, 10, 63, 69, 73) Increased duration of 
smoking and higher amounts of smoking are both associated with a dose dependently 
increased risk of GORS.(73) 
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1.3.2 Pathophysiology 
Tobacco smoking induces reflux by reducing the LOS resting pressure, facilitating 
gastric acid to reach the oesophagus.(136-138) In addition, tobacco smoking reduces the 
salivary bicarbonate secretion, which neutralises the acidity, and is associated with 
prolonged acid clearance time.(139, 140) 
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2 Objectives 
 
As GORD is a disease with considerable impact on both patients and society, we 
wanted to 1) obtain valid estimates of the occurrence of GORS in the general 
population, including a) changes in prevalence with calendar time, b) incidence, and c) 
spontaneous loss. In addition, as lifestyle is related to GORD, we wanted to 2) clarify 
whether changes in lifestyle are associated with improvement in GORS, with focus on 
the associations with a) weight loss and b) tobacco smoking cessation. 
 
2.1 Occurrence of gastro-oesophageal reflux (paper I) 
 
2.1.1 Changes in prevalence 
The prevalence of GORS has been reported from several populations, with a higher 
prevalence in more recent studies. However, the changes in prevalence over time in the 
same population remain uncertain. Our aim was to assess the changes in prevalence of 
GORS over time in the same population. 
 
2.1.2 Incidence 
The incidence of GORS has only been addressed in a few studies. Generally, these 
studies have a small sample size, a short follow-up time, or have been performed in a 
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selected population. Our aim was to assess the population-based cumulative incidence 
of GORS in a study of large sample size and long follow-up time. 
 
2.1.3 Spontaneous loss 
Loss of GORS without regular use of antireflux medication has only been addressed in 
a few studies with methodological issues. Our aim was to assess the population-based 
cumulative loss of GORS in study of large sample size and long follow-up time, 
excluding individuals using regular antireflux medication. 
 
2.2 Changes in lifestyle and gastro-oesophageal reflux (papers II-III) 
 
2.2.1 Weight loss and gastro-oesophageal reflux (paper II) 
Overweight is a strong risk factor of GORS (see section 1.2.2 above). However, 
whether weight loss reduces GORS is unclear. Our aim was to clarify whether weight 
loss reduces GORS in a large population-based cohort followed prospectively over 
time. 
 
2.2.2 Tobacco smoking cessation and gastro-oesophageal reflux (paper III) 
Tobacco smoking increases the risk of GORS (see section 1.3.1 above). Only the very 
short-term effects of smoking cessation on GORD outcomes has been evaluated and a 
randomized clinical trial of smoking cessation would be unethical and not feasible to 
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perform. Our aim was to clarify if tobacco smoking cessation improves GORS in a large 
population-based cohort followed prospectively over time.
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3 Materials and methods 
 
3.1 The Nord-Trøndelag Health Study 
 
3.1.1 Overview 
The Nord-Trøndelag Health Study (HUNT) is a population-based cohort study based on 
data collected at repeated health surveys. The first survey (HUNT 1) was performed 
from January 1984 through February 1986, the second survey (HUNT 2) was performed 
from August 1995 through June 1997, and the third survey (HUNT 3) was performed 
from October 2006 through June 2008. In addition, a short questionnaire (Mini-Q) was 
sent to the non-responders in HUNT 3 in 2009. All residents of Nord-Trøndelag County 
from 20 years of age have been invited to participate. The participants filled in written 
questionnaires on health related topics, risk factors, quality of life, and socioeconomic 
status and clinical measurements were performed. In HUNT 1, the main focus was on 
hypertension and diabetes.(141, 142) In HUNT 2 and 3, the questionnaires and 
measurements were extended considerably, including questions on GORS, and blood 
and urine samples were included.(143, 144) In each survey the residents were invited to 
participate at temporarily located examination sites staffed by trained personnel. A basic 
screening questionnaire accompanied the invitational letter to each survey and 
additional questionnaires were handed out to the participants at the examination sites. 
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3.1.2 Assessment of gastro-oesophageal reflux symptoms 
In HUNT 2 and HUNT 3 the questionnaires included an assessment of GORS. The 
participants were asked the following question: ‘To what degree have you had heartburn 
or acid regurgitation during the previous 12 months?’ The question had three response 
alternatives: ‘no complaints’, minor complaints’, or ‘severe complaints’. In HUNT 2 the 
GORS question was part of the basic screening questionnaire accompanying the 
invitational letter, but in HUNT 3 the GORS question was part of a second screening 
questionnaire that the participants received at the examination sites. However, the 
GORS question was also included in Mini-Q, which was sent to the non-responders in 
HUNT 3. In addition, frequency of GORS was assessed in Mini-Q through the 
following question: “If you have had heartburn or acid regurgitation during the previous 
12 months, how often do you have complaints?” The question had three response 
alternatives: ‘daily’, ‘weekly’, and ‘rarer’. Frequency of GORS was also assessed in a 
validation study after HUNT 2.(67) In the analyses, we have combined those who 
reported minor or severe complaints with GORS in the group ‘any GORS’ and those 
who reported severe complaints in the group ‘severe GORS’. In addition, a group ‘at 
least weekly GORS’ has been estimated from the information on degree of GORS from 
HUNT 2 and HUNT 3 and the information on frequency of GORS from the validation 
study after HUNT 2 and Mini-Q, respectively. 
 
3.1.3 Assessment of body mass index 
Weight and height were objectively measured under standardised conditions and by 
trained personnel at the examination sites in both HUNT 2 and HUNT 3. In Mini-Q, 
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weight and height measurements were self-reported. In paper II, the absolute change in 
BMI units between HUNT 2 and HUNT 3/Mini-Q was calculated and five categories 
reflecting this change were used in the analyses: <0.5 units change (reference category), 
0.5 to 1.5 units decrease, >1.5 to 3.5 units decrease, >3.5 units decrease, and ≥0.5 units 
increase. In paper III, the analyses were stratified by BMI categories as defined by the 
World Health Organization’s classification: 18.5 to 24.9 units (normal weight), 25.0 to 
29.9 units (pre-obese), and ≥30.0 units (obese).(128) Waist and hip circumference were 
also measured in HUNT 2 and HUNT 3, but not reported by the responders to Mini-Q. 
Thus, to increase the precision and reduce selection bias (see sections 5.1.2.2 and 
5.1.2.1 1) below), BMI was chosen over waist circumference as the measure of obesity. 
 
3.1.4 Assessment of tobacco smoking 
In HUNT 2, the participants were asked about their tobacco smoking status by 
answering yes or no to these questions: ‘Have you ever smoked daily?’, ‘Do you smoke 
cigarettes daily?’, ‘Do you smoke cigars or cigarillos daily?’, and ‘Do you smoke pipe 
daily?’ In HUNT 3 and Mini-Q, the participants were asked: ‘Do you smoke?’ The 
response alternatives to this question were: ‘no, I have never smoked’, ‘no, I have quit 
smoking’, ‘yes, cigarettes occasionally (parties/vacation, not daily)’, or ‘yes, cigarettes 
daily’. In paper III, those who quitted daily tobacco smoking or reduced daily smoking 
to only occasional smoking between HUNT 2 and HUNT 3/Mini-Q were defined as 
‘exposed’ to tobacco smoking cessation, and those who were persistent daily tobacco 
smokers at both time points were regarded as ‘unexposed’ to such cessation. In paper II, 
tobacco smoking was assessed as a co-variable by using the reported status in HUNT 
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3/Mini-Q. The categories included were ‘never smoker’, ‘previous smoker’, or ‘current 
smoker’, with the latter including those responding with ‘yes, cigarettes occasionally 
(parties/vacation, not daily)’ or ‘yes, cigarettes daily’. 
 
3.1.5 Assessment of co-variables 
Sex and age at participation at each survey were recorded for all participants. In paper I, 
the prevalence, incidence and loss of GORS were assessed for each sex and in age 
groups: <40, 40 to 49, 50 to 59, 60 to 69, and ≥70 years. In papers II and III, sex and 
age at follow-up in HUNT 3/Mini-Q were included as co-variables in the analyses. In 
addition, categories reflecting frequency of alcohol consumption (less than weekly or at 
least weekly), years of education (≤12 years or >12 years), and frequency of physical 
exercise (less than weekly or at least weekly) were included as co-variables in the 
analyses in papers II and III. Frequency of alcohol consumption was assessed in HUNT 
3/Mini-Q through the question: ‘About how often during the previous 12 months did 
you drink alcohol? (Do not include low-alcohol beer)’. This question had the following 
response alternatives: ‘4 to 7 times a week’, ‘2 to 3 times a week’, ‘about once a week’, 
‘2 to 3 times a month’, ‘about once a month’, ‘a few times a year’, ‘not at all the last 
year’, and ‘never drank alcohol’. We used weekly alcohol consumption as the cut-off 
value and those reporting consumption ‘about once a week’ or more frequent were 
included in the ‘at least weekly’ category and those reporting consumption ‘2 to 3 times 
a month’ or less frequent were included in the ‘less than weekly’ category. Education 
was not assessed in Mini-Q, so to reduce the number of participants with missing 
information on education, questionnaire data from HUNT 2 were used. In HUNT 2, 
3 Materials and methods  39 
Epidemiology of gastro-oesophageal reflux   
education was assessed with the following question: ‘What is your highest level of 
education?’ The response alternatives reflect both old and new educational systems in 
Norway: ‘primary school 7 to 10 years, continuation school, folk high school’, ‘high 
school, intermediate school, vocational school, 1 to 2 years high school’, ‘university 
qualifying examination, junior college, A levels’, ‘university or other post-secondary 
education, less than 4 years’, and ‘university/college, 4 years or more’. We defined 
university, other post-secondary education, and college as the higher level of education 
and this will require more than 12 years of education in Norway. The other levels of 
education require 12 years of education or less. Physical exercise was assessed in 
HUNT 3/Mini-Q with the following question: ‘How often do you exercise?’ The 
response alternatives to this question were: ‘never’, ‘less than once a week’, ‘once a 
week’, ‘2 to 3 times a week’, and ‘nearly every day’. We used weekly exercise as the 
cut-off value and those reporting exercise ‘once a week’ or more frequent were included 
in the ‘at least weekly’ category and those reporting exercise ‘less than once a week’ or 
less frequent were included in the ‘less than weekly’ category. 
 
3.2 The Norwegian Prescription Database 
 
3.2.1 Overview 
The Norwegian Prescription Database (NorPD) was established January 1, 2004. It 
contains data about drugs dispensed by prescription in Norway. All Norwegian 
pharmacies are required by legislation to report data on all prescriptions they are 
handling. Drugs that are purchased over the counter (OTC) without prescription are not 
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included. Through the use of the unique national identity number assigned to all 
Norwegian residents, it was possible to link the HUNT study to the NorPD. 
 
3.2.2 Assessment of antireflux medication 
Antireflux medication includes PPIs, H2RAs, antacids, and other drugs (misoprostol, 
sucralfate, bismuth subcitrate, and alginic acid). Until 2010, the prescription rules in 
Norway required a prescription from a physician for all PPIs or H2RAs, except for 
small packages of low dose H2RAs. As the NorPD was not established until 2004 we 
do not have information on antireflux medication at the time of HUNT 2. However, we 
were able to gather information on the prescribed medication among the participants in 
HUNT 3. We retrieved information from the NorPD by using the anatomical therapeutic 
chemical (ATC) classification system. We included all prescriptions of medications in 
the ATC A02 level (alimentary tract and metabolism, drugs for acid related disorders) 
and lower levels to include all usual antireflux medications. We collected information 
on dosage, package size, and number of packages for each single prescription. The 
information was retrieved from the HUNT 3 study period, from October, 2006 through 
June, 2008. By using the number of prescriptions and number of tablets in each 
prescription, average frequency of antireflux medication was estimated for each 
participant. To comply with the definition of GORD, we defined average weekly use of 
antireflux medication as the cut-off level. At least weekly use of antireflux medication 
was considered a proxy for GORD and less than weekly use of antireflux medication 
was considered not sufficient to be defined as GORD. In addition to the data from the 
NorPD, OTC antireflux medication was assessed in HUNT 3 with the following 
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question: ‘How often have you taken non-prescribed medication for the following 
complaints during the last month: heartburn or acid regurgitation?’ The response 
alternatives were: “never or rarely”, “1 to 3 times per week”, “4 to 6 times per week”, or 
“daily”. Thus, both prescribed and OTC antireflux medication in the study population 
during HUNT 3 should be accounted for. Only those who actually had a prescription of 
antireflux medication were included in the data from the NorPD and therefore it was not 
possible to distinguish between never users and participants with missing information 
on medication use. All participants with missing data on antireflux medication were 
therefore regarded as never users. 
 
3.3 Study design 
 
3.3.1 Cross-sectional studies 
Both HUNT 2 and HUNT 3 were cross-sectional surveys conducted in the same 
population during a defined time period, from August 1995 through June 1997 and from 
October 2006 through June 2008, respectively. Thus, prevalence of GORS could be 
assessed in this population at two time periods, approximately 11 years apart. As Mini-
Q was a non-responder study of those invited to participate in HUNT 3, we could also 
include the participants in Mini-Q in our study (HUNT 3/Mini-Q). 
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3.3.2 Longitudinal study 
The individuals who participated in both HUNT 2 and HUNT 3 or Mini-Q were 
prospectively followed from HUNT 2 to HUNT 3/Mini-Q. Thus, incidence of GORS 
and loss of GORS could be assessed. In addition, we could assess other variables 
associated with changes in GORS over time. 
 
3.4 Analyses 
 
3.4.1 Prevalence, incidence and loss of gastro-oesophageal reflux 
In paper I, prevalence of GORS was calculated as the proportion of participants in 
HUNT 2 and HUNT 3/Mini-Q who reported any (minor or severe) GORS or severe 
GORS, respectively. The prevalence of at least weekly GORS was estimated through 
assessment of both degree and frequency of complaints reported by those participating 
in the validation study after HUNT 2 and in Mini-Q. The proportion of participants with 
severe GORS and at least weekly GORS and the proportion of participants with minor 
GORS and at least weekly GORS in the validation study and Mini-Q were calculated. 
These proportions were then multiplied by the number of individuals with severe and 
minor GORS in HUNT 2 and HUNT 3, respectively, to get an estimate of at least 
weekly GORS in the two surveys. Cumulative incidence of GORS was calculated from 
the proportion of participants who reported no GORS in HUNT 2 and any or severe 
GORS in HUNT 3/Mini-Q, respectively. Cumulative loss of GORS was calculated from 
the proportion of participants who reported any or severe GORS in HUNT 2, 
respectively, but no GORS in HUNT 3/Mini-Q. In the latter analysis, those using 
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antireflux medication at least weekly in HUNT 3/Mini-Q were excluded to assess 
spontaneous loss of GORS only. Average annual cumulative incidence and spontaneous 
loss of GORS were calculated using the formula: (exp (cumulative proportion) – 1) / 11 
years (average annual percentage change). In addition, 95% CIs for the proportions 
were calculated. Prevalence, incidence, and spontaneous loss of GORS were assessed 
for each sex and by age groups: <40, 40 to 49, 50 to 59, 60 to 69, and ≥70 years. 
 
3.4.2 Logistic regression 
In paper I, logistic regression was used to statistically assess the differences in incidence 
and spontaneous loss of GORS for each sex and age group. The interaction term 
between sex and age groups was used in the model. In paper II and III, logistic 
regression was used to assess the association between weight loss and tobacco smoking 
cessation as exposures, respectively, and improvement in GORS as outcome. 
 
3.4.3 Generalised estimating equations 
Standard statistical models for analysing data, including logistic regression, assume 
independency between the measurements. However, repeated measurements over time 
in the same individual are not independent. Generalised estimating equations (GEE) are 
based on logistic regression and use the same model as independent data, but with a 
correlation structure added to adjust for the dependency over time. In paper I, the 
changes in prevalence of GORS from HUNT 2 to HUNT 3/Mini-Q was statistically 
assessed by GEE to account for the repeated assessments of GORS among many of the 
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participants. We used exchangeable correlation structure which assumes constant 
correlation over time. This is a valid assumption when the data has few measurements 
on a large sample of individuals as in the HUNT study.(145) In addition, we used a 
robust variance estimator to get valid standard errors. In the model, adjustments were 
made for sex and age by using the interaction term between sex and age groups as co-
variable. 
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4 Results 
 
4.1 Participation (papers I-III) 
 
4.1.1 The cross-sectional studies 
In HUNT 2, 93 898 residents of Nord-Trøndelag County above 20 years of age were 
invited. Of these, 1605 individuals were not eligible because they had moved out of the 
county or had died at the time of the survey. Of the eligible residents, 58 869 
individuals (64%) responded to the GORS questionnaire in HUNT 2. In HUNT 3, 
93 860 residents above 20 years of age were invited and 2330 of these were not eligible 
due to emigration or death. Of the eligible residents, 37 406 individuals responded to 
the GORS questionnaire in HUNT 3. In addition, 7591 of the non-participants in HUNT 
3 responded to the GORS questionnaire in Mini-Q. In total, 44 997 individuals (49%) 
responded to the GORS questionnaire in HUNT 3/Mini-Q (figure 2). 
 
4.1.2 The longitudinal study 
Of the 58 869 participants responding to the GORS questionnaire in HUNT 2, 10 535 
individuals were not eligible for follow-up in HUNT 3 due to emigration or death 
between the surveys. Of the eligible participants in HUNT 2, 29 610 individuals (61%) 
were followed up prospectively in HUNT 3/Mini-Q (figure 2). 
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1995      1997       2006        2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Flowchart of participants responding to the GORS questionnaires in HUNT 2 and HUNT 3/Mini-Q 
HUNT 2 HUNT 3/Mini-Q 
Participants responding to  
GORS questionnaire in 
HUNT 3/Mini-Q 
 
N=44 997 (49%) 
 
 
Invited 
N=93 898 
Eligible 
N=92 293 
Participants responding to  
GORS questionnaire in 
HUNT 2 
 
N=58 869 (64%) 
 
 
 
Invited 
N=93 860 
Invited 
Mini-Q 
N=45 500 
Eligible 
N=91 530
Participants 
HUNT 3 
N=37 406 
Participants 
Mini-Q 
N=7591 
Non-eligible 
N=1605 
Non-eligible 
N=2330
Non-
participants 
N=54 124 
Non-
participants 
N=33 424 
Non-eligible  
for follow-up 
N=10 535 
Eligible  
for follow-up 
N=48 334 
Lost  
to follow-up 
N=18 724 
Participants prospectively followed-up  
from HUNT 2 to HUNT 3/Mini-Q 
 
N=29 610 (61%) 
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4.2 Characteristics of participants 
 
4.2.1 Paper I 
In paper I we studied the occurrence of GORS for each sex and by age groups. In 
HUNT 2, 52% of the participants responding to the GORS questionnaire were women 
and 570 of these women reported to be pregnant. In HUNT 3/Mini-Q, 55% of the 
responders were women and 237 of these reported to be pregnant. All analyses included 
pregnant women, as analyses excluding them made no differences in the results. In 
HUNT 2, the mean age of the responders was 48.5 years (standard deviation (SD) 16.8 
years), ranging from 19 to 101 years of age. In HUNT 3/Mini-Q, the mean age was 52.1 
years (SD 16.0 years), ranging from 19 to 102 years. Among the participants who 
responded to the GORS questionnaire in both HUNT 2 and HUNT 3/Mini-Q, 54% were 
women and the mean age was 57.3 years at follow-up (SD 13.1 years), ranging from 29 
to 100 years of age. 
 
4.2.2 Paper II 
In paper II we studied the association between weight loss and improvement in GORS. 
At baseline in HUNT 2, 9299 individuals (31.4%) reported any GORS and 1553 
individuals (5.2%) reported severe GORS. Among those reporting any GORS in HUNT 
2, 2398 individuals (25.8%) reported no GORS at follow-up in HUNT 3/Mini-Q, i.e. 
“loss of any GORS” (table 1). Among those reporting severe GORS in HUNT 2, 284 
individuals (18.3%) reported no GORS at follow-up in HUNT 3/Mini-Q, i.e. “loss of 
48 
severe GORS” (table 1), 729 individuals (46.9%) reported minor GORS, and 1013 
(65.2%) reported no or minor GORS, i.e. “reduction of severe GORS” (table 1).  
The mean BMI among all the participants in paper II increased between HUNT 2 and 
HUNT 3/Mini-Q. The participants with loss or reduction of GORS had a lower increase 
in BMI than those with stable GORS (table 1). Those with loss or reduction of GORS 
were younger, had higher education, and used less antireflux medication than those with 
stable GORS (table 1). There was no difference in the proportion of current cigarette 
smokers among the subgroups (table 1). Of those reporting any GORS at baseline, the 
proportion of women was higher among those with loss of GORS compared to those 
with stable GORS at follow-up (table 1). Of those reporting severe GORS at baseline, 
alcohol consumption was more frequent among those with loss or reduction of GORS 
compared to those with stable GORS, and physical exercise was more frequent among 
those with loss or reduction of GORS (table 1). 
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4.2.3 Paper III 
In paper III we studied the association between tobacco smoking cessation and 
improvement in GORS. In this paper we focused on the participants reporting severe 
GORS at baseline in HUNT 2 due to the heterogenetic nature of individuals reporting 
minor GORS (see section 5.3.3 below). Among the 1553 participants with severe GORS 
in HUNT 2, 486 (31%) were daily tobacco smokers and were included in the study. Of 
these participants, 182 quitted smoking and 31 reduced to occasional smoking in HUNT 
3/Mini-Q. In total, 213 (44%) were previous daily smokers while 251 (52%) were 
persistent daily smokers in HUNT 3/Mini-Q. In both these groups, about 60% were 
using antireflux medication at least weekly (figure 3). The mean BMI was similar 
between the groups, but obesity was less common among the persistent daily smokers. 
Compared to the previous daily smokers, the persistent daily smokers were 
characterized by higher female representation, lower mean age, lower education, lower 
level of physical exercise, and lower alcohol consumption (table 2). 
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Figure 3 Flowchart of participants in paper III 
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4.3 Occurrence of gastro oesophageal reflux (paper I) 
 
4.3.1 Changes in prevalence 
The changes in prevalence of GORS over time in the same population were assessed. 
During the average 11-year period between HUNT 2 (1995 to 1997) and HUNT 3/Mini-
Q (2006 to 2009) the prevalence of any GORS increased by 30%, from 31.4% (95% CI 
31.0% to 31.7%) to 40.9% (95% CI 40.4% to 41.3%), and the prevalence of severe 
GORS increased by 24%, from 5.4% (95% CI 5.2% to 5.6%) to 6.7% (95% CI 6.4% to 
6.9%). The OR of any and severe GORS in 2006 to 2009 was 1.46 (95% CI 1.43 to 
1.49) and 1.20 (95% CI 1.15 to 1.26), respectively, compared with 1995 to 1997 after 
adjustment for sex and age. The prevalence increased for both sexes and all age groups 
(table 3, figure 4-5). In the validation study after HUNT 2, at least weekly GORS were 
reported by 25% of those participants with minor GORS and by 95% of those with 
severe GORS. In Mini-Q, the corresponding rates were 31% and 98%. The estimated 
prevalence of at least weekly GORS increased by 47% between 1995 to 1997 and 2006 
to 2009, from 11.6% (95% CI 11.4% to 11.9%) to 17.1% (95% CI 16.7% to 17.4%) 
(table 4, figure 6).  
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Figure 4 Prevalence of any GORS for each sex and age groups in 1995-1997 (HUNT 2) and 2006-2009 
(HUNT 3/Mini-Q) with 95% CI (vertical lines) 
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Figure 5 Prevalence of severe GORS for each sex and age groups in 1995-1997 (HUNT 2) and 2006-
2009 (HUNT 3/Mini-Q) with 95% CI (vertical lines) 
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Figure 6 Prevalence of estimated at least weekly GORS for each sex and age groups in 1995-1997 
(HUNT 2) and 2006-2009 (HUNT 3/Mini-Q) with 95% CI (vertical lines) 
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4.3.2 Incidence 
Between HUNT 2 (1995 to 1997) and HUNT 3/Mini-Q (2006 to 2009), the cumulative 
incidence of any GORS was 29.1% (95% CI 28.4% to 29.7%), which corresponded to 
an average annual incidence of 3.07% (95% CI 2.99% to 3.14%). The incidence 
increased with increasing age for women, while it was stable with age for men. Women 
younger than 40 years of age had the lowest incidence of any GORS, but in older age 
groups there was no difference in the incidence of any GORS between the sexes (table 
5, figure 7). The cumulative incidence of severe GORS was 2.5% (95% CI 2.3 to 2.7%), 
which corresponded to an average annual incidence of 0.23% (95% CI 0.21 to 
0.25%).There was a slightly increased incidence of severe GORS with increasing age 
for women, but it was stable with age for men. Women aged 60 to 69 years had the 
highest incidence of severe GORS (table 5, figure 7). 
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Figure 7 Cumulative incidence of any and severe GORS for each sex and age groups (age at follow-up) 
between 1995-1997 (HUNT 2) and 2006-2009 (HUNT 3/Mini-Q) with 95% CI (vertical lines) 
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4.3.3 Spontaneous loss 
Between HUNT 2 (1995 to 1997) and HUNT 3/Mini-Q (2006 to 2009), the cumulative 
loss of any GORS was 22.7% (95% CI 21.9% to 23.6%), when excluding the 286 
participants (12%) using antireflux medication at least weekly. This corresponded to an 
average annual spontaneous loss of 2.32% (95% CI 2.23% to 2.42%). Women younger 
than 40 years of age had the highest spontaneous loss of any GORS. The spontaneous 
loss decreased with increasing age for both sexes, but this was more pronounced among 
women. There was no difference in spontaneous loss of any GORS between the sexes in 
older age groups (table 6, figure 8). The cumulative loss of severe GORS was 12.6% 
(95% CI 10.9% to 14.2%), when excluding the 89 participants (31%) using antireflux 
medication at least weekly. This corresponded to an average annual spontaneous loss of 
1.22% (95% CI 1.05% to 1.40%). The spontaneous loss decreased with increasing age 
for both sexes, but this was particularly evident among women (table 6, figure 8). 
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Figure 8 Cumulative spontaneous loss of any and severe GORS for each sex and age groups (age at 
follow-up) between 1995-1997 (HUNT 2) and 2006-2009 (HUNT 3/Mini-Q) with 95% CI (vertical lines) 
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Epidemiology of gastro-oesophageal reflux 
4.4 Associations with lifestyle and gastro-oesophageal reflux (papers II-III) 
 
4.4.1 Weight loss and gastro-oesophageal reflux (paper II) 
Weight loss was dose-dependently associated with loss or reduction of GORS. When 
antireflux medication was used at least weekly, weight loss was associated with a 
particular increased treatment success. Among participants with no or less than weekly 
use of antireflux medication, the adjusted OR of loss of any GORS among participants 
with >3.5 units decrease in BMI was 1.98 (95% CI 1.45 to 2.72) compared to 
participants with <0.5 units change in BMI (table 7, figure 9). Among participants with 
at least weekly antireflux medication, the corresponding OR was 3.95 (95% CI 2.03 to 
7.65) (table 7, figure 10). In the severe GORS cohort, there was no association between 
weight loss and GORS among participants with no or less than weekly antireflux 
medication (table 7, figure 11-12). However, among participants using antireflux 
medication at least weekly, the adjusted OR of reduction of severe GORS was 2.12 
(95% CI 0.89 to 5.02) (table 7, figure 13) and the adjusted OR of loss of severe GORS 
was 3.11 (95% CI 1.13 to 8.58) (table 7, figure 14). 
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Figure 9 Adjusted OR with 95% CI for loss of any GORS by change in BMI when using no or less than 
weekly antireflux medication 
 
 
Figure 10 Adjusted OR with 95% CI for loss of any GORS by change in BMI when using at least weekly 
antireflux medication 
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Figure 11 Adjusted OR with 95% CI for reduction of severe GORS by change in BMI when using no or 
less than weekly antireflux medication 
 
 
Figure 12 Adjusted OR with 95% CI for loss of severe GORS by change in BMI when using no or less 
than weekly antireflux medication 
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Figure 13 Adjusted OR with 95% CI for reduction of severe GORS by change in BMI when using at least 
weekly antireflux medication 
 
 
Figure 14 Adjusted OR with 95% CI for loss of severe GORS by change in BMI when using at least 
weekly antireflux medication 
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4.4.2 Tobacco smoking cessation and gastro-oesophageal reflux (paper III) 
Among daily tobacco smokers with severe GORS in HUNT 2 using no or less than 
weekly antireflux medication, there was no statistically significant association between 
tobacco smoking cessation and GORS status in HUNT 3/Mini-Q (adjusted OR 0.95, 
95% CI 0.39 to 2.30), compared with persistent daily smoking (table 8 and figure 15). 
However, among daily tobacco smokers with severe GORS in HUNT 2 using at least 
weekly antireflux medication, tobacco smoking cessation was associated with an 
improvement in GORS status from severe to no or minor complaints in HUNT 3/Mini-
Q (adjusted OR 1.78, 95% CI 1.07 to 2.97), compared with persistent daily smoking 
(table 8 and figure 15). This association was stronger among individuals within the 
normal weight range (adjusted OR 5.67, 95% CI 1.36 to 23.64), but disappeared among 
overweight individuals (table 8 and figure 16). There was no association between 
tobacco smoking cessation and GORS status among individuals with minor GORS in 
HUNT 2. 
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Figure 15 Adjusted OR with 95% CI of improvement in severe GORS by tobacco smoking cessation, 
comparing previous daily tobacco smokers with persistent daily tobacco smokers as reference. Restricted 
to those using no or less than weekly antireflux medication and stratified by BMI. Model adjusted for sex, 
age, alcohol consumption, education, and physical exercise. 
 
Figure 16 Adjusted OR with 95% CI of improvement in severe GORS by tobacco smoking cessation, 
comparing previous daily tobacco smokers with persistent daily tobacco smokers as reference. Restricted 
to those using at least weekly antireflux medication and stratified by BMI. Model adjusted for sex, age, 
alcohol consumption, education, and physical exercise.
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5 Discussion 
 
5.1 Materials and methods 
 
5.1.1 Study design 
The thesis was based on two repeated population-based cross-sectional surveys 
conducted approximately 11 years apart, where the entire adult population in a 
geographically determined area were invited. The population-based design reduces 
selection bias compared with hospital or clinic based studies (see section 5.1.2.1 1) 
below). The two separate surveys assessed a wide range of health related variables, 
including exposures, complaints, and diseases, collected through self-administered 
questionnaires, clinical measurements, and blood samples, so there was no selection 
based on specific exposures or diseases. In paper I, the prevalence of GORS was 
estimated among all the participants at the two time points. In addition, the prospective 
cohort design, nested within the two surveys, was used to follow the individuals 
participating at both times. This design made it possible to identify incident cases, i.e. 
individuals with no GORS at baseline and present GORS at follow-up, and cases with 
loss or reduction of GORS, i.e. individuals with present GORS at baseline and no or 
reduced GORS at follow-up. The prospective design also reduces recall bias of the 
variables that were studied (see section 5.1.2.1 2) below). However, as the follow-up 
was at one time point and not a continuous registration of each new case, only 
cumulative incidence/loss was possible to assess and not incidence/loss rates. On the 
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other hand, a cohort study with continuous registration of new cases would be much 
more time and resource consuming and probably not a feasible design with a chronic 
and relapsing disease as GORD. In papers II and III, the cohort was studied 
prospectively with a case-control design to assess the association between 
loss/reduction of GORS as outcome and weight loss or tobacco smoking cessation as 
exposure, respectively. Specifically, the cases were those participants who reported 
present GORS at baseline and no or reduced GORS at follow-up and the controls were 
those with stable GORS at both time points. The controls were selected from the same 
source population as the cases and independent of exposure status. This reduces the risk 
of selection bias (see section 5.1.2.1 1) below). The main exposures in papers II and III 
were defined as change in BMI and tobacco smoking status between the two surveys, 
respectively. In addition, the design used in this thesis allowed simultaneous assessment 
of a number of other variables than the ones under direct study to adjust for 
confounding (see section 5.1.2.1 3) below). 
 
5.1.2 Internal validity and precision 
There are two main types of error in observational research, systematic error and 
random error, affecting internal validity and precision, respectively. Internal validity 
relates to the inference among the source population, as opposed to external validity or 
generalisability, which relates to the inference to populations outside the source 
population (see section 5.1.3 below). 
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5.1.2.1 Systematic error 
Systematic error, often termed bias, affects the internal validity of the results. High 
internal validity, i.e. low level of systematic error, means that the results actually reflect 
what the study aimed to measure. Systematic error can be divided into: 1) selection bias, 
2) information bias, and 3) confounding (and reversed causality). 
 
1) Selection bias 
Selection bias occurs when the selection of study participants influence the relationship 
under study, i.e. when the relationship is different among the actual participants than 
among those theoretically eligible to participate. In a case-control study, it is essential 
that the controls are selected from the same source population as the cases and 
independently of exposure to avoid selection bias. The population-based design, where 
all controls are sampled directly from the same source population as the cases, protects 
against selection bias compared to hospital- or clinic-based populations. In hospital- or 
clinic-based studies, the source population of a specific hospital or clinic is often not 
well defined and controls from the hospital or clinic are often not selected 
independently of exposure in the source population. Selection bias might also occur if 
participants in a study are not a random sample of the source population or the 
participation rate is low. In such cases, the exposure of those participating might be 
different from the source population and this might affect the association under study.  
In HUNT 2, participation was lower among men, the youngest (20 to 29 years), and the 
oldest (≥90 years). Among invited, 67% of the men versus 76% of the women, 49% of 
the youngest, and 53% of the oldest participated, respectively. However, a non-
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participation study shortly after HUNT 2 found that the main reasons for non-
participation among the young (20 to 44 years) were that they had moved or were 
absent from the county for a long time, were busy in job, or had forgot to participate or 
had no specific reason for non-participation.(143) Thus, non-participation among the 
young was probably not related to exposure or disease and should not influence the 
results. Among the older (≥70 years), the main reasons for non-participation were 
regular follow-up by a physician or hospital, immobilisation by disease, or that they had 
moved or were absent from the county for a long time.(143) So, non-participation 
among the older was related to disease and the results should be interpreted with caution 
in this group. The response rate in our study dropped from 64% in HUNT 2 to 49% in 
HUNT 3/Mini-Q. An important reason for this drop in participation rate was that the 
GORS question was moved from the mailed screening questionnaire following the 
invitation in HUNT 2 to the follow-up questionnaire received at the examination sites in 
HUNT 3. In addition, many participants in HUNT 2 (n=10 535) had moved out of the 
county or had died before HUNT 3. Again, the participation was lower among men, the 
youngest (20 to 29 years), and the oldest (≥90 years). Among invited, 49% of the men 
versus 59% of the women, 31% of the youngest, and 18% of the oldest participated, 
respectively. The main reason for non-participation in HUNT 3 was lack of time or 
inconvenient session (57% men and 51% women).(144) In addition, a non-participant 
study after HUNT 3 found that participation was dependent on socioeconomic status, 
type of symptoms, and diseases, including cardiovascular diseases and diabetes.(146) 
So, this should be taken into consideration when interpreting the results. The response 
rates in our study opens up for the possibility of some level of selection bias. On the 
other hand, as the purpose of the HUNT study was to perform an extensive investigation 
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of common diseases and exposures using a wide range of health related variables, non-
participation due to GORS is unlikely. In Mini-Q and HUNT 3, respectively, 29.9% and 
43.1% reported any GORS; 4.3% and 7.1% reported severe GORS; and 5.7% and 8.2% 
used at least weekly antireflux medication. These differences were retained also after 
stratification by sex and age. The distribution of the key variables associated with 
GORS was also assessed. In Mini-Q and HUNT 3, respectively, 49% and 56% were 
women; the mean age was 45.9 and 53.4 years; the mean BMI was 26.1 and 27.2; there 
were no major differences in the proportions of none or daily cigarette smokers; 34% 
and 38% drank at least weekly alcohol; and 69% and 79% reported at least weekly 
physical exercise. The lower prevalence of GORS in Mini-Q compared to HUNT 3 may 
indicate a selection of individuals with more complaints in the study population than in 
the source population. This may overestimate the occurrence of GORS. However, this 
bias is reduced with the inclusion of the participants in Mini-Q in the study population. 
The lower prevalence of GORS in Mini-Q may also in part be explained by the lower 
age and lower BMI of this population. In the cohort followed up from HUNT 2 to 
HUNT 3/Mini-Q, the response rate was 61%. Selection bias due to loss to follow-up is 
probably small since there were only minor differences in the distribution of the study 
variables among all the HUNT 2 participants (N=58 869) compared with the cohort 
which was followed up (N=29 610): there was no difference in the mean BMI (26 
kg/m2) or mean alcohol consumption (2.5 times/month); the proportion of women was 
52% and 54%; the mean age was 48.5 years and 45.8 years; the proportion of never 
smokers was 47% and 48% and of daily smokers 30% and 27%; the proportion with 
>12 years of education was 21% and 24%; and the proportion who did no exercise 
weekly was 9% and 6%, respectively. Among the participants who participated at both 
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HUNT 2 and HUNT 3/Mini-Q, missing values on the included variables were generally 
low. In paper I, only 7 of the 44 997 participants in HUNT 3/Mini-Q had missing values 
on sex. In papers II-III, the amount of missing values was higher due to the inclusion of 
more variables in the analyses. In paper II, less than 2% of the participants had missing 
values in the crude analyses. When including all co-variables, the rate of participants 
with missing values reached 12.8%. However, the estimated ORs did not differ 
substantially between the crude analyses and the fully adjusted analyses. In paper III, 
the maximum rate of participants with missing values in the analyses reached 4.5%. We 
did no further corrections due to missing values because the amount of participants with 
missing values was low and probably without substantial influence on the results. As all 
Norwegian pharmacies are obligated by Norwegian regulations to send information on 
every handled prescription to the NorPD, the information on prescriptions from the 
NorPD should be complete. 
 
2) Information bias 
Information bias occurs by misclassification of the variables under study, i.e. the 
variables in the study do not measure correctly what they are supposed to measure. 
Misclassification may be differential or non-differential. Misclassification of exposure 
is differential if it is different for those with and without the outcome under study and 
non-differential if it is not related to the outcome. Misclassification of disease is 
likewise differential if it is related to the exposure status of the participants and non-
differential if it is not related to the exposure. Differential misclassification may either 
overestimate or underestimate the association studied and lead to serious error. Non-
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differential misclassification usually only dilutes the association studied, a less serious 
error which does not generate spurious effects. Misclassification can occur due to recall 
bias. This might happen in a case-control study if the exposure information has to be 
recalled retrospectively by the participants. Often this type of recall bias is differential, 
because individuals with disease tend to recall exposure differently than individuals 
without disease. The prospective design used in this thesis protects against recall bias, 
as exposure information was assessed at both time points. Moreover, if recall bias is 
present, it will most likely be non-differential as the participants were unaware of the 
outcome under study. 
The recall period of 12 months might introduce information bias, but individuals with 
severe or frequent GORS are likely to report this correctly due to the impact on quality 
of life. The average 11 year time period between the two assessments makes short term 
fluctuations in GORS impossible to evaluate. In paper I, the analysis of incident GORS 
may then also have included recurrent symptoms and not only genuinely new cases, and 
loss of GORS may not necessarily mean a true recovery, but rather a temporary relief of 
symptoms. However, the 12 months recall period most likely reduced the problem with 
fluctuating symptoms. The outcome in this thesis is GORS, classified by the response to 
a written questionnaire on complaints with heartburn and acid regurgitation. In English, 
“heartburn” and “regurgitation” are known to be words that the general public not 
understands adequately. However, in Norwegian this is much less of a problem. The 
Norwegian words “brystbrann”/”halsbrann” and “sure oppstøt” used in this thesis are 
frequently used in the common language and are readily understood by the general 
public in the same way as health care professionals and researchers do. Moreover, any 
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misclassification is likely to be non-differential, as exposure status should not affect the 
understanding of the questionnaire. There is no uniform, perfect definition of GORD, 
but the Montreal definition acknowledges that moderate/severe symptoms occurring 
more than 1 day a week in population-based studies often are considered troublesome 
by patients and could be used as a definition of GORD. As the HUNT 2 validation and 
Mini-Q showed that 95% to 97% of the participants reporting severe GORS had at least 
weekly complaints, respectively, severe GORS have a high specificity for true GORD. 
The main exposure in paper II is weight loss, defined by reduction in BMI between 
HUNT 2 and HUNT 3/Mini-Q. In HUNT 2 and HUNT 3, height and weight were 
objectively measured under standardised conditions and by trained personnel at 
examination sites. This makes misclassification unlikely and if present non-differential 
because neither the participants nor the personnel where aware of GORS as a study 
outcome. In Mini-Q, height and weight were self-reported, possibly introducing some 
misclassification of BMI in this limited subpopulation. The mean BMI was lower 
among the participants in Mini-Q than in HUNT 3 (26.1 and 27.2, respectively), 
probably because self-reported weight is an underestimation of the actual weight. 
However, the number of individuals from Mini-Q was limited to n=938 (10.1%) and 
n=190 (12.2%) in the any GORS cohort and the severe GORS cohort, respectively. 
Again, misclassification is likely to be non-differential. In addition, assuming that self-
reported weight is an underestimate of the actual weight, this would overestimate any 
weight loss from baseline in the study, and dilute the effect of weight loss on loss or 
reduction of GORS, make the presented ORs closer to the null. 
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In paper III, the main exposure was tobacco smoking cessation between HUNT 2 and 
HUNT 3/Mini-Q. Tobacco smoking was assessed by the participants through 
questionnaires and again potential misclassification is likely to be non-differential as the 
participants were not aware of GORS as an outcome. The categorisation of tobacco 
smoking used in the study is crude and do not reflect duration or amount of smoking, 
besides daily smoking. However, pathophysiological data suggests that the effect of 
tobacco smoking is very short lived, so duration or amount of smoking should be of less 
importance. In addition, daily smoking is a common cut-off level in observational study, 
making comparisons with other studies easier. The co-variables alcohol consumption, 
education, and physical exercise were all dichotomised. This is a simplification, but the 
cut-offs are chosen to reflect common and sensible differences in the value of the 
variables. On the other hand, higher levels of categorisation would reduce the statistical 
power and increase the risk of type II errors, i.e. not able to show an actual association. 
The NorPD uses the ATC classification system and the records include dosage, package 
size, and number of packages for each single prescription. So, the information is 
systematic and detailed with easy access. However, drugs purchased without 
prescription are not included in the NorPD. Instead, the participants in HUNT 3 
reported OTC use of antireflux medication through questionnaires and these data are 
more prone to bias than the systematic collection of data in the NorPD. On the other 
hand, the information on the most potent and frequently used drugs, the PPIs and 
H2RAs, were collected from the NorPD. 
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3) Confounding and reversed causality 
Confounding may be thought of as confusion or mixing of effects. The apparent effect 
of the exposure under study on the outcome is distorted because the effect of extraneous 
factors is mistaken for the effect of the exposure. A confounding factor must in general 
be associated with both the outcome and exposure under study, but not an effect of the 
exposure or outcome.(147) In observational research, confounding is often controlled 
for by study design, stratification, restriction, matching, or multivariable regression 
analyses. The latter method is preferred if several potential confounders are present, as 
in papers II and III.  
In papers II and III, we restricted the choice of co-variables to those variables that were 
most consistently associated with GORS in population-based studies from Western 
populations: sex,(5, 9, 66, 70, 75, 76) age,(5, 6, 66, 70, 75) alcohol consumption,(9, 63, 
69) socioeconomic status represented by years of education,(8, 74, 75) and physical 
exercise.(69, 73) One could argue that other variables should be included as well, as 
variables reflecting dietary patterns and genetic variables, but such data were not 
available. Moreover, if the model is busy with too many variables it does not allow 
proper adjustment. Residual confounding by known and unknown factors can never be 
excluded in observational research due to information bias. Sex and age were included 
as possible confounders because they were associated with the prevalence of GORS in 
paper I. In addition, sex and age are typical proxy variables or surrogates of unmeasured 
confounders, e.g. diseases have often different occurrence between women and men and 
increasing age is associated with increasing rate of disease. Education was chosen to 
reflect socioeconomic status. Socioeconomic status is known to effect general health 
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and education is used as a valid proxy variable of the possible unmeasured confounders 
related to socioeconomic status. Alcohol consumption and physical exercise have both 
been related to GORD in pathophysiological and epidemiological studies and they are 
also associated with the main exposures under study. None of the included potential 
confounding variables are likely to be an effect of the exposures or outcome. Other 
variables could perhaps also have been included as confounders, but we restricted the 
number of confounders to those considered most relevant by pathophysiological and 
epidemiological studies to avoid spurious effects by the adjustments. Antireflux 
medication was not considered a confounder according to the definition above. 
However, to account for the use of antireflux medication, the analyses were stratified by 
antireflux medication and the results presented for each strata. In paper III, stratification 
by BMI was used to show the effect modification of BMI on tobacco smoking 
cessation. As we were interested in the association between weight loss and tobacco 
smoking cessation on GORS status at follow-up, we used the values of the possible 
confounders at follow-up and not at baseline. The value of a confounder at the time of 
the outcome assessment is probably more relevant than the value of the confounder 11 
years before. The only exception was education, where we used the value recorded in 
HUNT 2. Education was not assessed in Mini-Q, so to reduce the amount of missing 
values the baseline value was used. Moreover, due to the study design, all participants 
were above 20 years of age at participation and the level of education was probably 
determined already at baseline for the vast majority of participants. An alternative 
approach considered, was to include variables reflecting the change in the confounders 
as well. However, the interpretation of changing co-variables in observational research 
is complex and difficult to interpret. The changing co-variables might interact in 
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complex manners and they might act as both intermediates and confounders depending 
on the sequence and timing of the changes. In addition, this would heavily reduce the 
statistical power due to more subgroup analyses. Moreover, the number participants 
with missing values would also increase, opening for selection bias. Residual 
confounding due to simplification and inaccurate information on the confounding 
variables or due to other unknown factors cannot be ruled out. The co-variables were 
dichotomised, except for age, and this is probably an oversimplification of the 
information within each variable, making residual confounding possible. However, 
dichotomisation improves the statistical power and the robustness of the full model. 
In observational research causality cannot be implied due to the lack of control of 
extraneous factors, as opposed to large and well-done randomised trials. Even the 
opposite conclusions of effect may be drawn due to reverse causality in non-
experimental studies. Cross-sectional studies are especially prone to this as the exposure 
and outcome are assessed at the same time. Reversed causality may appear if the 
outcome under study affects the exposure. An example from the HUNT study is the 
reduced risk of severe GORS found among frequent coffee drinkers in HUNT 2.(73) In 
this analysis coffee seems to protect against severe GORS. However, coffee is known to 
be a trigger of reflux by reducing the LOS pressure and individuals with severe GORS 
probably abstain from frequent coffee drinking. As that probably is the case, individuals 
without GORS drink more coffee than those with severe GORS and coffee drinking is 
associated with reduced risk of severe GORS, i.e. reversed causality. In papers II and 
III, the use of longitudinal data with assessment of change in the main exposures and 
outcome over time protect against reversed causality. In addition, the 
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pathophysiological and epidemiological evidence makes it unlikely that weight loss and 
tobacco smoking cessation should increase the risk of GORS. Although a randomised 
trial is the most reliable method to establish disease causality in humans, such a trial of 
tobacco smoking cessation would be unethical to perform, leaving observational studies 
the best alternative. Moreover, comparisons of results from randomised trails and cohort 
studies have yielded very similar findings. 
 
5.1.2.2 Random error 
Random error affects the precision of the results. Random error is determined by the 
variability within the measured variables, the sample size, and variability related to the 
sampling of the specific study participants. Random error is reduced with low 
measurement variability and with large sample size. There will always be some degree 
of variability related to the specific study participants compared with the broader 
population of interest. 
One of the main strengths of the HUNT study is the large sample size, reducing random 
error and increasing the precision of the results. This is shown in paper I with the 
narrow CIs around the estimated prevalence rates. The large sample size also makes 
extensive subgroup analyses possible. However, high precision provides no assurance 
against systematic error. Even if the precision is high, we cannot know if the exposure is 
responsible for the observed effect or whether differences in effect are important for the 
outcome under study. 
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5.1.3 Generalisability 
Generalisability or external validity of the results in a study means how well the results 
can be transferred to other populations than the source population. Generalisability also 
heavily depends on a high internal validity. With some exceptions, the population of 
Nord-Trøndelag is considered to be representative of the Norwegian population at large. 
The residents of Nord-Trøndelag have slightly lower average income and education 
than the Norwegian average and Nord-Trøndelag County lacks a large city (>25 000 
inhabitants). On the other hand, the population of Nord-Trøndelag is stable and 
homogenous with the large majority being Caucasians.(144, 148) So, the results should 
be generalisable internationally to similar populations. 
 
5.2 Ethical considerations 
 
The HUNT study has been approved by the Regional Committee for Medical and 
Health Research Ethics, Central Norway, and has obtained consent to handle personal 
information by the Data Inspectorate. All participants in the HUNT study received 
written information about the study and signed a consent form when they participated. 
As part of the consent, information on research projects using the HUNT material is 
published on the official HUNT internet pages.  
Our study has been approved by the Regional Committee for Medical and Health 
Research Ethics, Central Norway. In HUNT 3, the consent included approval of linkage 
with other registries, including the NorPD. However, at the time of HUNT 2 the NorPD 
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was not established and the consent did not include this registry. To allow linkage of 
data between HUNT 2 and the NorPD, we have obtained exemption from the 
confidentiality by the Norwegian Directorate of Health and consent to handle personal 
information by the Data Inspectorate. 
 
5.3 Main results and implications 
 
5.3.1 Occurrence of gastro-oesophageal reflux (paper I) 
The prevalence of GORS increased substantially between 1995 to 1997 and 2006 to 
2009. This will affect the quality of life for a considerable amount of people. In 
addition, it will have implications for the society with increased demands on the health 
care system and lost work productivity. Even if the risk is low for each individual 
suffering from GORS, the increasing prevalence of GORS will most likely contribute to 
an increasing incidence of oesophageal adenocarcinoma. GORS are usually of a chronic 
and persistent nature, but we found that some lost their symptoms without medication. 
To understand why and how these individuals spontaneously lost their symptoms might 
have implications for preventive and management strategies in GORD.  
 
5.3.2 Weight loss and gastro-oesophageal reflux (paper II) 
Both patients and clinicians often report that weight loss improves the occurrence and 
severity of GORS, but the scientific evidence has not been convincing. However, in this 
study weight loss was dose-dependently associated with reduction in GORS. Weight 
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loss was also associated with an increased treatment success with antireflux medication. 
Due to the observational design of the study, strict causality cannot be implied. 
However, the pathophysiology, the consistent and dose related association between 
weight loss and reduction in GORS, and the preserved association after adjustment for 
possibly important confounders argues for a valid, biological relation which is not due 
to bias. As the validation study after HUNT 2 and Mini-Q showed that 95% and 98% of 
those reporting severe GORS had at least weekly complaints, respectively, the study 
suggests that weight loss also could benefit patients with GORD according to the 
Montreal definition. However, weight loss was not sufficient to reduce severe GORS 
without regular use of antireflux medication. This probably reflects an advanced stage 
of GORD in these participants, as oesophagitis and symptoms related to the presence of 
a hiatal hernia, which do not resolve only with weight loss. Weight loss probably 
reduces the frequency of TLOSRs and the association of TLOSRs with reflux episodes, 
which are not the main pathophysiologic mechanisms of hiatal hernia. A fairly modest 
weight loss seems to reduce GORS and the data also indicates that greater benefits 
might be seen with even larger weight loss. Moreover, weight loss was associated with 
a better treatment success with antireflux medication. This might be especially useful in 
patients with refractory GORS despite regular use of antireflux medication to improve 
the response to medical therapy. 
 
5.3.3 Tobacco smoking cessation and gastro-oesophageal reflux (paper III) 
Tobacco smoking cessation was associated with an improvement in GORS only among 
normal weight individuals using antireflux medication at least weekly. There was no 
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such pattern in individuals with minor GORS, overweight, or those using antireflux 
medication less than weekly. The results are consistent with the pathophysiology (136-
140) and a randomised controlled trial of smoking cessation would be unethical to 
perform. Due to the low absolute number of individuals who totally quit smoking 
(n=182), we defined the ‘exposure’ in this study to be a combination of those quitting 
smoking and those only reducing daily smoking to occasional smoking (n=31). Even so, 
we found an association between the ‘exposure’, i.e. reduced tobacco smoking, and the 
outcome, i.e. improved GORS. This suggests that total smoking cessation would 
increase the chance of success even more than apparent from our study. We found no 
association between tobacco smoking cessation and improvement in minor GORS. This 
probably reflects the heterogenetic nature of individuals reporting minor GORS, 
including individuals with functional syndromes. These syndromes have other 
pathophysiological mechanisms which at least in part are not related to 
gastroesophageal reflux or tobacco smoking. The lack of improvement in overweight 
individuals might be explained by overweight being a stronger contributor to GORS 
than tobacco smoking. The pathophysiology of GORS is probably driven by the weight 
in overweight and obese individuals and smoking has a minor role, but in individuals of 
normal weight smoking has a more important role in the pathophysiology. The lack of 
improvement among those using no or less than weekly antireflux medication, suggests 
that the individuals with severe GORS have a more advanced stage of GORD, i.e. 
oesophagitis or symptoms related to the presence of hiatal hernia, which does not 
resolve only with tobacco smoking cessation. However, weight loss and tobacco 
smoking cessation might reduce the need for antireflux medication over time. In 
addition, these lifestyle measures are also advisable due to the effects on general health. 
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As tobacco smoking as well as GORS is associated with adenocarcinoma of the 
oesophagus and gastric cardia, persons with GORS should be advised to refrain from 
smoking.(149-152) 
 
5.4 Comparison with previous research 
 
5.4.1 Occurrence of gastro-oesophageal reflux (paper I) 
Comparison with previous research on the occurrence of GORS is inherently difficult 
because the definitions and settings used vary between studies. We have restricted our 
comparisons to population-based studies conducted in Western populations. Only few 
previous studies have assessed the prevalence of GORS in the same population at two 
different time points or followed-up a cohort over time and addressed the cumulative 
incidence and loss of GORS. Due to low number of participants, most of these studies 
have not been able to investigate the occurrence of GORS by sex and age groups. 
 
5.4.1.1 Changes in prevalence 
Two studies conducted in Olmsted County, Minnesota, USA, found that the prevalence 
of at least weekly heartburn had increased from 13.2% (n=835; aged 30 to 64 years) to 
17.8% (n=1511; aged 25 to 74 years) from the 1980s to the 1990s.(4, 11) A study from 
Göteborg Municipality in the western part of Sweden, found that the prevalence of any 
GORS had increased from 20% to 21% (n=337; aged 20 to 79 years) in 1986 to 22% to 
25% (n=197) at follow-up 10 years later.(65, 153) Another Swedish study from 
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Östhammar Municipality in the eastern part of Sweden, found that the prevalence of any 
GORS had increased from 18.9% (n=1156; aged 20 to 79 years) to 19.4% (n=877) 
between 1988 and 1995.(154) Finally, a study from Fyn County, Denmark, found a 
stable prevalence of at least mild GORS of 22% (n=6781; aged 40 to 65 years) in 1998 
to 1999 and 5 years later (n=5578).(155) All these studies had considerably lower 
number of participants (range 197 to 5578 participants) than the HUNT study, but over 
all they confirm the conclusion that the prevalence of GORS seems to be increasing. 
 
5.4.1.2 Incidence 
A study from the western part of København County, Denmark, including 2987 
participants from 30 to 60 years of age reported an annual incidence of any GORS of 
13% to 19% and of frequent GORS of 1% to 3% between 1982 to1984 and 1987 to 
1988.(156) In a study from Östhammar Municipality, Sweden, including 1059 
participants from 20 to 79 years of age the annual incidence of predominant GORS was 
0.05% and of GORS with other concurrent gastrointestinal symptoms of 0.75% between 
1988 and 1989. In a study from Olmsted County, Minnesota, including 690 participants 
from 30 to 64 years of age the cumulative onset rate of heartburn several times a weekly 
or daily was 2.7% after 12 to 20 months follow-up in 1988 to 1991, corresponding to an 
average annual incidence of 1.6% to 2.7%.(16) In a study from Göteborg Municipality, 
Sweden, including 197 participants from 20 to 79 years of age the annual incidence of 
any GORS was 1.2% to 1.8% between 1986 and 1996.(153) Finally, in a study from 
Fyn County, Denmark, including 5578 participants from 40 to 65 years of age the 
annual incidence of at least mild GORS was 2.2% between 1998 to 1999 and 
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2004.(155) Except for the study from København, these studies comply with our results 
(average annual incidence of any and severe GORS of 3.07% and 0.23%, respectively) 
and the incidence has been stable or possibly increasing over the last two decades. 
 
5.4.1.3 Spontaneous loss 
In København County, Denmark, the cumulative loss of any GORS was 27% to 37% 
between 1982 to 1984 and 1987 to 1988, corresponding to an average annual loss of 
6.2% to 9.0% and the cumulative loss of frequent GORS was 59% to 77%, 
corresponding to an average annual loss of 16.1% to 23.2%.(156) In Olmsted County, 
Minnesota, the cumulative loss of heartburn several times a week or daily was 47.8% in 
1988 to 1991, corresponding to an average annual loss of 36.9% to 61.3%.(16) In 
Göteborg Municipality, Sweden, the annual loss of any GORS was 1.1% to 1.3% 
between 1986 and 1996.(153) Finally, in Fyn County, Denmark, the annual loss of at 
least mild GORS was 8.6% between 1998 to 1999 and 2004.(155) Except for Göteborg 
Municipality, Sweden, these figures deviate from our results (average annual 
spontaneous loss of any and severe GORS of 2.32% and 1.22%, respectively). 
However, the large number of participants in the HUNT study, the long follow-up time, 
and ability to adjust for antireflux medication argues for validity. In addition, we found 
a substantial association between spontaneous loss of GORS and age. 
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5.4.2 Weight loss and gastro-oesophageal reflux (paper II) 
There has only been one previous population-based study assessing the association 
between weight loss and GORS. In this study from Olmsted County, Minnesota, 637 
individuals were followed over a median of 10.5 years and no association between 
weight loss of >10 lb (>4.5 kg) and GORS was found. The mean age was 61 years at 
follow-up and 54.8% were females. Major limitations of this study were the use of self-
reported height and weight and a large loss to follow-up from the initial 4793 
participants. The mean BMI of the initial participants was 26.5, but the mean BMI at 
baseline of the actual 637 participants followed-up was not reported.(157) However, in 
the Nurses’ Health Study the OR of at least weekly GORS was 0.64 (95% CI 0.42 to 
0.97) among participants with at least 3.5 decrease in BMI compared with participants 
with no change in BMI.(129) Two randomised, double-blind, sham controlled trials of 
gastric balloon distension on extremely obese patients with pH-verified GORD also 
found an effect of weight loss on oesophageal pH. In these studies, individuals with 
high grade oesophagitis (Los Angeles classification grade C or D (82, 83)) or large (>3 
cm) hiatus hernia on endoscopy were excluded. Weight loss was achieved by a weight 
reducing program using dietary guidance, physical exercise, and behavioural 
therapy.(158, 159) The first trial of 42 patients with mean BMI 43.4 found improvement 
in total time of pH <4 from 5.60% to 3.72% (p<0.05) after a decrease in mean BMI of 
3.8 after 13 weeks of treatment.(158) The second trial of 28 patients with mean BMI 
43.3 found improvement in upright time of pH <4 from 8.0% to 5.5% (p<0.05) and 
decreased number of meal and postprandial reflux episodes from 49.0 to 32.1 (p<0.05) 
after a decrease in body weight of 12.4 kg after 13 weeks of treatment.(159) An 
uncontrolled prospective study of 34 patients with mean BMI 23.5 and troublesome 
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GORS also found improvement in a modified DeMeester questionnaire symptom score 
after 6 weeks with dietary advice. These individuals had either normal endoscopy or 
low grade oesophagitis (grade I in the Savary-Miller classification (160)) and a decrease 
in mean BMI of 1.7.(161) Another uncontrolled prospective study of 18 volunteers with 
mean BMI 43.5 and GORS, found an improvement in the distress subscale of the 
gastroesophageal reflux disease symptom assessment scale (162, 163) from a mean of 
1.28 to 0.72 (p=0.0004) and reduction in the Johnson-DeMeester score (54, 164) from a 
mean of 34.7 to 14.0 (p=0.023) after a mean of 4 days on a very low-carbohydrate diet 
and an average weight loss of 1.7 kg.(165) However, a randomized trial of 20 obese 
patients with mean BMI 31.4 at inclusion with pH-verified reflux, erosive oesophagitis, 
and daily GORS, did not find any effect of a very low-calorie diet after 6 months on 
measures of pH, oesophagitis, or GORS despite decrease in mean BMI of 2.6 to 
4.8.(166) This study included participants with hiatus hernia, which contributes to the 
occurrence of GORD and is irreversible with weight loss. 
 
5.4.3 Tobacco smoking cessation and gastro-oesophageal reflux (paper III) 
Three previous studies have addressed smoking cessation and GORD but found 
conflicting results. One study found no influence of 24 hours refrainment from smoking 
on 24-hour pH-measurements of the distal oesophagus in 10 smokers with GORS who 
regularly smoked about 20 cigarettes a day.(167) Another study found no immediate 
effect of smoking cessation on total oesophageal acid exposure in 8 smoking men with 
moderate to severe endoscopic evidence of GORD who smoked at least one pack of 
cigarettes a day.(168) The third study, however, found a reduced distal oesophageal acid 
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exposure in 14 smokers with daily heartburn for at least 6 months and endoscopy or 
biopsy evidence of reflux oesophagitis who smoked at least 20 cigarettes a day who 
abstained from smoking for 48 hours.(169) Our study is the first epidemiological 
investigation testing whether tobacco smoking cessation improves GORS and the first 
study that evaluates such cessation in a long-term perspective.
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6 Conclusions 
GORD is a disease which affects a large proportion of our population and the 
occurrence of GORD seems to be increasing for both sexes and in all age groups. There 
is an association between weight loss and tobacco smoking cessation and improvement 
in GORS. Moreover, weight loss and tobacco smoking cessation are associated with an 
increased chance of treatment success with antireflux medication. Thus, weight loss and 
tobacco smoking cessation could be important measures to prevent and treat GORD.
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 INTRODUCTION 
 Gastroesophageal refl ux disease (GERD) is a highly prevalent 
disease in Western populations ( 1,2 ), associated with a decreased 
health-related quality of life ( 3,4 ) and an increased risk of esopha-
geal adenocarcinoma ( 5,6 ). Th e Montreal defi nition and classifi -
cation of GERD states that:  “ GERD is a condition which develops 
when the refl ux of stomach contents causes troublesome symptoms 
and / or complications ” and the defi nition recognizes that heartburn 
and acid regurgitation are characteristic symptoms of GERD ( 7,8 ). 
Overweight, defi ned according to the World Health Organization ’ s 
classifi cation as body mass index (BMI) of  ≥ 25  kg / m 2 ( 9 ), increases 
the risk of gastroesophageal refl ux symptoms (GERS) ( 10 – 12 ) and 
is independently associated with esophageal adenocarcinoma ( 11 ). 
Th e increasing weight seen in the general population will have 
unfortunate eff ects on the prevalence of GERD ( 13 – 15 ). Weight 
loss may be of great importance in the prevention and treatment 
of the many individuals with GERD. Th e aim of this study was to 
clarify if weight loss reduces GERS in a large population-based 
cohort followed prospectively over time. 
 METHODS 
 Study population and design 
 Th e study was performed as part of a large population-based 
study, the Nord-Tr ø ndelag health study (the HUNT study). Th e 
HUNT study is an on-going prospective cohort study based 
 Weight Loss and Reduction in Gastroesophageal 
Reﬂ ux. A Prospective Population-Based Cohort Study: 
The HUNT Study 
 Eivind  Ness-Jensen ,  MD 1 , 2 ,  Anna  Lindam ,  MSc 3 ,  Jesper  Lagergren ,  MD, PhD 3 , 4 and  Kristian  Hveem ,  MD, PhD 1 
 OBJECTIVES:  High body mass index (BMI) is an established risk factor of gastroesophageal reﬂ ux symptoms 
(GERS). The aim of this study was to clarify if weight loss reduces GERS. 
 METHODS:  The study was part of the Nord-Tr ø ndelag health study (the HUNT study), a prospective population-
based cohort study conducted in Nord-Tr ø ndelag County, Norway. All residents of the county from 
20 years of age were invited. In 1995 – 1997 (HUNT 2) and 2006 – 2009 (HUNT 3), 58,869 and 
44,997 individuals, respectively, responded to a questionnaire on heartburn and acid regurgitation. 
Among these, 29,610 individuals (61 % response rate) participated at both times and were included 
in the present study. The association between weight loss and reduction of GERS was calculated 
using logistic regression. The analyses were stratiﬁ ed by antireﬂ ux medication and the results 
adjusted for sex, age, cigarette smoking, alcohol consumption, education, and physical exercise. 
 RESULTS:  Weight loss was dose-dependently associated with a reduction of GERS and an increased treatment 
success with antireﬂ ux medication. Among individuals with   >  3.5 units decrease in BMI, the 
adjusted odds ratio (OR) of loss of any (minor or severe) GERS was 1.98 (95 % conﬁ dence interval 
(CI) 1.45 – 2.72) when using no or less than weekly antireﬂ ux medication, and 3.95 (95 % CI 
2.03 – 7.65) when using at least weekly antireﬂ ux medication. The corresponding ORs of loss of 
severe GERS was 0.90 (95 % CI 0.32 – 2.55) and 3.11 (95 % CI 1.13 – 8.58). 
 CONCLUSIONS:  Weight loss was dose-dependently associated with both a reduction of GERS and an increased 
treatment success with antireﬂ ux medication in the general population. 
 Am J Gastroenterol 2013; 108:376–382;  doi: 10.1038/ajg.2012.466; published online 29 January 2013 
 1 HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology ,  Levanger ,  Norway ;  2 Department 
of Internal Medicine, Levanger Hospital, Nord-Tr ø ndelag Hospital Trust ,  Levanger ,  Norway ;  3 Upper Gastrointestinal Research, Department of Molecular Medicine 
and Surgery, Karolinska Institutet ,  Stockholm ,  Sweden ;  4 Division of Cancer Studies, King ’ s College London ,  London ,  UK .  Correspondence:  Eivind Ness-Jensen, 
MD ,  HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology ,  Forskningsvegen 2 ,  N-7600 
 Levanger ,  Norway . E-mail:  eivind.ness-jensen@ntnu.no 
 Received 19 June 2012; accepted 5 October 2012 
see related editorial on page 383
© 2013 by the American College of Gastroenterology The American Journal of GASTROENTEROLOGY
377
 E
S
O
P
H
A
G
U
S 
 Weight Loss and Gastroesophageal Reflux 
on repeated health surveys of the entire adult population of 
Nord-Tr ø ndelag County, Norway. All residents in the county 
from 20 years of age have been invited to participate in three sur-
veys, entitled HUNT 1 (1984 – 1986), HUNT 2 (1995 – 1997), and 
HUNT 3 (2006 – 2008). Th e HUNT study includes data on a wide 
range of health-related items gathered from written questionnaires 
answered by the participants, clinical examinations performed by 
trained personnel, and blood samples taken from the participants 
( 16 ). GERS were assessed in HUNT 2 and HUNT 3, and these 
two surveys constituted the base of the present study. In addition, 
GERS were assessed in a  “ non responder study ” (Mini-Q) aft er 
HUNT 3 in 2009, where those who did not participate in HUNT 3 
were invited ( 2,16 ). Th e individuals who participated in HUNT 2 
and were followed-up in Mini-Q were also eligible for inclusion 
in the present study ( Figure 1 ). 
 Assessment of GERS 
 GERS were assessed by a questionnaire in HUNT 2 (1995 – 1997) 
and HUNT 3 / Mini-Q (2006 – 2009). Th e participants replied to 
the question:  “ To what degree have you had heartburn or acid 
regurgitation during the previous 12 months? ” with one of three 
response alternatives:  “ no complaints, ”  “ minor complaints, ” or 
 “ severe complaints. ” In a validation study aft er HUNT 2, 25 % of 
those reporting minor complaints and 95 % of those reporting 
severe complaints had at least weekly symptoms ( 10 ). In Mini-Q, 
where frequency of complaints was also assessed, the correspond-
ing proportions were 31 % and 98 % ( 2 ). We defi ned  “ any GERS ” to 
include all participants reporting minor or severe complaints and 
 “ severe GERS ” to include only those reporting severe complaints. 
 Assessment of BMI 
 BMI equals weight in kilograms divided by the square height in 
meters (kg / m 2 ). Weight and height were objectively measured 
under standardized conditions and by trained personnel at screen-
ing stations in both HUNT 2 and HUNT 3. In Mini-Q, weight and 
height measurements were self-reported. 
 Assessment of covariables 
 Covariables in the analyses were chosen using accepted 
criteria for a confounding factor i.e., being associated with the 
outcome (GERS), associated with the exposure (weight loss), and 
not an eff ect of the exposure or outcome under study ( 17 ). Th e 
variables selected as potential confounders were sex, age, cigarette 
smoking, alcohol consumption, education, and physical exercise. 
Th ese covariables were assessed through questionnaires in HUNT 3
 / Mini-Q, except for education, which was assessed in HUNT 2. 
Th e participants reported cigarette smoking status, frequency of 
alcohol drinking during the previous 12 months, length of educa-
tion, and average frequency of physical exercise. 
 Assessment of antireﬂ ux medication 
 Data on antirefl ux medication, i.e., proton pump inhibitors 
(PPIs), histamine-2-receptor antagonists (H2RAs), or antacids, 
were gathered from HUNT 3 and from the Norwegian Prescrip-
tion Database (NorPD). Until 2010, proton pump inhibitors and 
H2RAs (except small packages of low-dose H2RAs) have only 
been available in Norway through a prescription from a physi-
cian, and only small packages of low-dose H2RAs and antacids 
have been available over the counter. In HUNT 3, the frequency of 
over-the-counter antirefl ux medication use was assessed through 
written questionnaires. Since 2004, data on all prescribed medica-
tion in Norway have been collected in the NorPD. By linkage of 
the HUNT study and the NorPD, data on all prescribed antirefl ux 
medication among the study participants were gathered. Using 
number of prescriptions and number of tablets in each prescrip-
tion, average frequency of antirefl ux medication was estimated 
during the HUNT 3 study period. Th us, all antirefl ux medica-
tion should be accounted for in HUNT 3: over-the-counter use 
through the HUNT 3 questionnaires and prescribed use through 
the NorPD. Only those who were actually prescribed an antire-
fl ux medication were included in the data from the NorPD, and 
therefore it was not possible to distinguish between never users 
and participants with missing information on medication use. 
All participants with missing data on antirefl ux medication were 
therefore regarded as never users. 
Eligible for
follow-up
N=48,334
1995 1997 2006 2009
HUNT 2 HUNT 3/Mini-Q
Participants
HUNT 3/Mini-Q
N=44,997
Invited
N=93,898
Eligible
N=92,293
Participants
HUNT 2 
N=58,869
Invited
N=93,860
Invited
Mini-Q
N=45,500
Eligible
N=91,530
Participants
HUNT 3
N=37,406
Participants
Mini-Q
N=7,591 
Non eligible
N=1,605
Non eligible
N=2,330
Non
participants
N=54,124
Non
participants
N=33,424
Non eligible
for follow-up
N=10,535
Lost to
follow-up
N=18,724
Study population
N=29,610 (61%)
Prospectively followed up from
HUNT 2 to HUNT 3/Mini-Q
 Figure 1 .  Flowchart of participants. Number of individuals ( N ) at each 
stage and the response rate ( % ). The response rate was calculated from 
those eligible for follow-up, excluding those who were no longer residents 
in the county or had deceased (non eligible for follow-up). 
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 Statistical methods 
 Logistic regression was used to analyze the association between 
weight loss and reduction of GERS, providing odds ratios (ORs) 
with 95 % confi dence intervals (CIs). Th e participants who had 
any GERS at baseline (HUNT 2) and no GERS at follow-up 
(HUNT 3 / Mini-Q), defi ned as  “ loss of any GERS, ” were com-
pared with those who had any GERS at both time points, i.e., 
 “ stable any GERS. ” Th e participants who had severe GERS at 
baseline and no or minor GERS at follow-up, defi ned as  “ reduc-
tion of severe GERS, ” were compared with those who had severe 
GERS at both time points, i.e.,  “ stable severe GERS. ” Finally, 
those who had severe GERS at baseline and no GERS at follow-
up, defi ned as  “ loss of severe GERS, ” were compared with those 
who had severe GERS at both time points, i.e.,  “ stable severe 
GERS. ” Th e absolute change in BMI units between the two time 
points was calculated and fi ve categories refl ecting this change 
were used in the analyses:   <  0.5 units change (reference cate-
gory), 0.5 – 1.5 units decrease,   >  1.5 – 3.5 units decrease,   >  3.5 
units decrease, and ≥0.5 units increase. In the statistical model, 
adjustments were made by categorization of age (  <  40, 40 – 49, 
50 – 59, 60 – 69, or  ≥ 70 years), cigarette smoking status (never 
smoker, previous smoker, or current smoker), frequency of 
alcohol consumption (less than weekly or at least weekly), years 
of education ( ≤ 12 years or   >  12 years), and frequency of physi-
cal exercise (less than weekly or at least weekly). Antirefl ux 
medication was not considered a confounder according to the 
defi nition above. Instead, the analyses were stratifi ed into two 
groups of antirefl ux medication use at follow-up: no or less than 
weekly or at least weekly. Th e analyses were performed with 
the statistics and data analysis soft ware Stata, version 11.2 
(StataCorp LP, College Station, TX). 
 Study approval 
 Th e study was approved by the Regional Committee for Medical 
and Health Research Ethics, Central-Norway (ID 4.2009.328). All 
participants in the HUNT study signed a written consent form 
before participating, which stated the purpose of the study and 
the possibility of future research and linkage to other registries. 
 RESULTS 
 Participants 
 In HUNT 2 (1995 – 1997) and HUNT 3 / Mini-Q (2006 – 2009), 
58,869 individuals (64 % response rate) and 44,997 individu-
als (49 % response rate) reported their complaints with GERS, 
respectively. Among these, 29,610 individuals participated in both 
surveys and were included in the present study. Th is corresponds 
to a response rate of 61 % at follow-up, aft er excluding the 10,535 
participants in HUNT 2 who were no longer residents in the 
county at the time of HUNT 3 / Mini-Q or had deceased before 
HUNT 3 / Mini-Q (non eligible for follow-up;  Figure 1 ). 
 Characteristics 
 At baseline (HUNT 2), 9,299 individuals (31.4 % ) reported any 
GERS (any GERS cohort) and 1,553 individuals (5.2 % ) reported 
severe GERS (severe GERS cohort). Of the any GERS cohort, 
2,398 individuals (25.8 % ) reported no GERS at follow-up in 
HUNT 3 / Mini-Q, i.e.,  “ loss of any GERS ” ( Table 1 ). Of the severe 
GERS cohort, 284 individuals (18.3 % ) reported no GERS at 
follow-up in HUNT 3 / Mini-Q, i.e.,  “ loss of severe GERS ” 
( Table 1 ), 729 individuals (46.9 % ) reported minor GERS, and 
1,013 (65.2 % ) reported no or minor GERS, i.e.,  “ reduction of 
severe GERS ” ( Table 1 ). 
 Th e mean BMI among all the participants increased between the 
two time points. Th e participants with loss or reduction of GERS 
had a lower increase in BMI than those with stable GERS ( Table 1 ). 
Th ose with loss or reduction of GERS were younger, had higher 
education, and used less antirefl ux medication than those with sta-
ble GERS for both cohorts ( Table 1 ). Th ere was no diff erence in 
the proportion of current cigarette smokers among the subgroups 
( Table 1 ). In the any GERS cohort, the proportion of women was 
higher among those with loss of GERS compared with those with 
stable GERS ( Table 1 ). In the severe GERS cohort, alcohol con-
sumption was more frequent among those with loss or reduction 
of GERS compared with those with stable GERS, and physical 
exercise was more frequent among those with loss or reduction of 
GERS ( Table 1 ). 
 Association between weight loss and GERS 
 In the crude analyses, without considering antirefl ux medica-
tion or any potential confounder, weight loss was dose-depend-
ently associated with loss or reduction of GERS ( P value for 
trend  ≤ 0.012;  Table 2 ). When stratifi ed by antirefl ux medica-
tion, weight loss was associated with an increased treatment suc-
cess with antirefl ux medication when used at least weekly ( Table 2 ). 
Among participants with no or less than weekly antirefl ux 
medication, there was a twofold increase in the adjusted odds of 
loss of any GERS among participants with   >  3.5 units decrease 
in BMI compared with participants with   <  0.5 units change in 
BMI (OR 1.98, 95 % CI 1.45 – 2.72;  Table 2 ). Among participants 
with at least weekly antirefl ux medication, the corresponding 
odds increased fourfold (OR 3.95, 95 % CI 2.03 – 7.65;  Table 2 ). 
Th e association between weight loss and any GERS was dose 
dependent, regardless of antirefl ux medication ( P value for 
trend   <  0.001;  Table 2 ). In the severe GERS cohort, there was 
no association between weight loss and GERS among partici-
pants with no or less than weekly antirefl ux medication. Th e 
adjusted ORs of reduction and loss of severe GERS among 
those with   >  3.5 units decrease in BMI compared with those 
with   <  0.5 units change in BMI was 0.58 (95 % CI 0.16 – 2.10; 
 Table 2 ) and 0.90 (95 % CI 0.32 – 2.55;  Table 2 ), respectively, and 
there was no dose-response association ( P value for trend 0.804 
and 0.189, respectively;  Table 2 ). However, among those with at 
least weekly antirefl ux medication, the corresponding OR was 
2.12 (95 % CI 0.89 – 5.02;  Table 2 and  Figure 2 ) and 3.11 (95 % 
CI 1.13 – 8.58;  Table 2 and  Figure 3 ), respectively, and there was 
a dose-response association ( P value for trend 0.008 and 0.047, 
respectively;  Table 2 ). As the crude and adjusted ORs were simi-
lar when stratifi ed by antirefl ux medication, only the adjusted 
data are presented in  Table 2 . 
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 DISCUSSION 
 In this study, weight loss was dose-dependently associated with 
a reduction of GERS, especially among those with the highest 
decrease in BMI. Weight loss was also associated with an increased 
treatment success with antirefl ux medication. 
 Th e major strengths of this study are (i) the population-
based design, reducing selection bias; (ii) the large sample size, 
reducing the risk of chance fi ndings and making subgroup analy-
ses possible; (iii) the prospective design, minimizing recall bias; 
(iv) the large selection of variables assessed in the HUNT study, 
making adjustments for potential confounders possible; and 
(v) the linkage with the NorPD, complementing the data on anti-
refl ux medication. Th e limitations are (i) the loss to follow-up 
between the two time points, making selection bias possible; 
 Table 1 .  Characteristics of cohort reporting gastroesophageal reﬂ ux symptoms (GERS) a in HUNT 2 and HUNT 3 / Mini-Q ( N =29,610) 
  Stable any GERS  Loss of any GERS b  Stable severe GERS  Reduction of severe GERS b  Loss of severe GERS b 
 Number ( % )  6,901 (74.2)  2,398 (25.8)  540 (34.8)  1,013 (65.2)  284 (18.3) 
 BMI (kg / m  2  ), HUNT 2 
  Mean (s.d.)  27.3 (4.0)  27.2 (4.3)  27.7 (4.2)  28.1 (4.3)  27.9 (4.3) 
  Missing, no. ( % )  23 (0.3)  21 (0.9)  2 (0.4)  5 (0.5)  2 (0.7) 
 BMI (kg / m  2  ) change c 
  Mean (s.d.)  1.3 (2.4)  0.5 (2.7)  1.3 (2.4)  0.9 (2.7)  0.6 (2.8) 
  Missing, no. ( % )  78 (1.1)  46 (1.9)  7 (1.3)  19 (1.9)  7 (2.5) 
 Sex 
  Women, no. ( % )  3,415 (49)  1,271 (53)  277 (51)  521 (51)  143 (50) 
 Age (years), HUNT 3 / Mini-Q 
  Mean (s.d.)  59.8 (12.6)  57.4 (14.1)  60.8 (12.7)  60.2 (13.6)  58.7 (14.5) 
 Cigarette smoking, HUNT 3 / Mini-Q 
  Never, no. ( % )  2,428 (35.2)  921 (38.4)  188 (34.8)  304 (30.0)  79 (27.8) 
  Previous, no. ( % )  2,332 (33.8)  737 (30.7)  182 (33.7)  383 (37.8)  120 (42.3) 
  Current, no. ( % )  1,822 (26.4)  631 (26.3)  141 (26.1)  279 (27.5)  73 (25.7) 
  Missing, no. ( % )  319 (4.6)  109 (4.5)  29 (5.4)  47 (4.6)  12 (4.2) 
 Alcohol consumption, HUNT 3 / Mini-Q 
   <  Weekly, no. ( % )  4,292 (62.2)  1,498 (62.5)  363 (67.2)  649 (64.1)  173 (60.9) 
  ≥ Weekly, no. ( % )  2,377 (34.4)  816 (34.0)  153 (28.3)  327 (32.3)  103 (36.3) 
  Missing, no. ( % )  232 (3.4)  84 (3.5)  24 (4.4)  37 (3.7)  8 (2.8) 
 Education, HUNT 2 
  ≤ 12 Years, no. ( % )  5,602 (81.2)  1,837 (76.6)  469 (86.9)  842 (83.1)  233 (82.0) 
   >  12 Years, no. ( % )  1,162 (16.8)  511 (21.3)  56 (10.4)  146 (14.4)  41 (14.4) 
  Missing, no. ( % )  137 (2.0)  50 (2.1)  15 (2.8)  25 (2.5)  10 (3.5) 
 Physical exercise, HUNT 3 / Mini-Q 
   <  Weekly, no. ( % )  1,672 (24.2)  576 (24.0)  156 (28.9)  272 (26.9)  71 (25.0) 
  ≥Weekly, no. ( % )  5,047 (73.1)  1,754 (73.1)  363 (67.2)  721 (71.2)  210 (73.9) 
  Missing, no. ( % )  182 (2.6)  68 (2.8)  21 (3.9)  20 (2.0)  3 (1.1) 
 Antireﬂ ux medication d , HUNT 3 
  Never or   <  weekly, no. ( % ) e  3,742 (54.2)  2,112 (88.1)  87 (16.1)  505 (49.9)  195 (68.7) 
  ≥Weekly, no. ( % )  3,159 (45.8)  286 (11.9)  453 (83.9)  508 (50.1)  89 (31.3) 
 a GERS: self-reported degree of complaints with heartburn or acid regurgitation during the previous 12 months. 
 b Loss of any GERS: any GERS at baseline, no GERS at follow-up; Reduction of severe GERS: severe GERS at baseline, no or minor GERS at follow-up; loss of severe 
GERS: severe GERS at baseline, no GERS at follow-up. The severe GERS group is a subset of the any GERS group. 
 c Body mass index (BMI) change: BMI HUNT 3 / Mini-Q  −  BMI HUNT 2. 
 d Antireﬂ ux medication: proton pump inhibitors, histamine-2-receptor antagonists, and antacids. 
 e Participants with no information on antireﬂ ux medication were included in never or   <  weekly category. 
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diff erence in the mean BMI (26  kg / m 2 ) or mean alcohol consump-
tion (2.5 times / month); the proportion of women was 52 and 54 % ; 
the mean age was 48.5 years and 45.8 years; the proportion of 
never smokers was 47 and 48 % and of daily smokers 30 and 27 % ; 
the proportion with   >  12 years of education was 21 and 24 % ; and 
the proportion who did no exercise weekly was 9 and 6 % , respec-
tively. Th e 12-month recall period used in the questionnaire is a 
suboptimal long period to recall GERS. However, this should not 
be a major threat to the validity of the study, as most people with 
GERS, at least of a more severe type, are likely to be able to report 
their symptoms. Th e passage of 11 to 12 years between the surveys 
does not capture the short-term fl uctuations in symptoms in the 
individual subject. Moreover, some people with GERS might have 
(ii) the 12-month recall period used in the questionnaire, making 
recall bias possible; (iii) the long time period between the assess-
ments of GERS, making short-term fl uctuations in GERS impossi-
ble to evaluate; (iv) residual confounding, which cannot be excluded 
in observational research, although the choice of covariables was 
restrictive to avoid spurious eff ects; and (v) self-reported height and 
weight in Mini-Q, reducing the measurement accuracy of BMI. 
 Th e Nord-Tr ø ndelag County is representative of the Norwe-
gian population at large, making the fi ndings generalizable ( 18 ). 
Selection bias due to loss of follow-up is probably small as there 
were only minor diff erences in the distribution of the study vari-
ables among all the HUNT 2 participants ( N  =  58,869) compared 
with the cohort that was followed-up ( N  =  29,610): there was no 
 Table 2 .  Odds ratio (OR) with 95 % conﬁ dence interval (95 % CI) for loss or reduction of gastroesophageal reﬂ ux symptoms (GERS) a 
compared with stable GERS by change in body mass index (BMI) b and antireﬂ ux medication c 
  Loss of any GERS d  Reduction of severe GERS d  Loss of severe GERS d 
 Change in BMI (kg / m  2  )  No.  OR  95 % CI  No.  OR  95 % CI  No.  OR  95 % CI 
 Crude 
  ≥ 0.5 increase  5,542  0.72  0.63 – 0.82  897  0.83  0.63 – 1.10  897  0.77  0.55 – 1.09 
   <  0.5 change  1,589  1.00  Reference  278  1.00  Reference  278  1.00  Reference 
  0.5 – 1.5 decrease  970  1.22  1.03 – 1.46  157  0.88  0.59 – 1.33  157  0.90  0.55 – 1.48 
   >  1.5 – 3.5 decrease  770  1.38  1.15 – 1.66  137  1.87  1.16 – 3.02  137  1.11  0.67 – 1.83 
   >  3.5 decrease  304  2.42  1.88 – 3.11  58  1.32  0.70 – 2.47  58  1.51  0.79 – 2.88 
  P value for trend f    <  0.001    0.001    0.012  
  Missing ( % )  124  (1.3)   26  (1.7)   26  (1.7)  
 No or less than weekly antireﬂ ux medication  e 
 ≥ 0.5 increase  3,100  0.67  0.57 – 0.78  304  0.74  0.36 – 1.51  304  0.72  0.43 – 1.19 
   <  0.5 change  939  1.00  Reference  95  1.00  Reference  95  1.00  Reference 
  0.5 – 1.5 decrease  616  1.14  0.92 – 1.40  65  0.50  0.20 – 1.22  65  0.83  0.41 – 1.67 
   >  1.5 – 3.5 decrease  485  1.25  0.99 – 1.56  54  1.64  0.49 – 5.48  54  1.13  0.56 – 2.31 
   >  3.5 decrease  198  1.98  1.45 – 2.72  22  0.58  0.16 – 2.10  22  0.90  0.32 – 2.55 
  P value for trend f    <  0.001    0.804    0.189  
  Missing ( % )  516  (8.8)   52  (8.8)   52  (8.8)  
 At least weekly antireﬂ ux medication  e 
 ≥ 0.5 increase  2,022  0.99  0.67 – 1.45  518  1.04  0.71 – 1.51  518  0.81  0.42 – 1.56 
   <  0.5 change  507  1.00  Reference  145  1.00  Reference  145  1.00  Reference 
  0.5 – 1.5 decrease  267  1.29  0.75 – 2.19  78  1.16  0.66 – 2.03  78  0.94  0.36 – 2.48 
   >  1.5 – 3.5 decrease  213  1.79  1.05 – 3.05  67  2.24  1.19 – 4.21  67  0.91  0.32 – 2.55 
   >  3.5 decrease  66  3.95  2.03 – 7.65  30  2.12  0.89 – 5.02  30  3.11  1.13 – 8.58 
  P value for trend f    <  0.001    0.008    0.047  
  Missing ( % )  370  (10.7)   123  (12.8)   123  (12.8)  
 a GERS: self-reported degree of complaints with heartburn or acid regurgitation during the previous 12 months. 
 b Change in BMI: BMI HUNT 3 / Mini-Q  −  BMI HUNT 2. 
 c Antireﬂ ux medication: proton pump inhibitors, histamin-2-receptor antagonists, and antacids. 
 d Loss of any GERS: any GERS at baseline, no GERS at follow-up; Reduction of severe GERS: severe GERS at baseline, no or minor GERS at follow-up; loss of severe GERS: 
severe GERS at baseline, no GERS at follow-up. The severe GERS group is a subset of the any GERS group. 
 e Adjusted for sex, age, cigarette smoking, alcohol consumption, education, and physical exercise. 
 f P value for trend: Wald test for linear trend. 
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developed Barrett ’ s esophagus between the surveys, which might 
reduce symptoms, although the refl ux disease remains. However, 
this should be limited to only a few people in the study. In Mini-Q, 
height and weight were self-reported, reducing measurement accu-
racy of BMI in this subpopulation. However, the number of indi-
viduals from Mini-Q was limited to  n  =  938 (10.1 % ) and  n  =  190 
(12.2 % ) in the any GERS cohort and the severe GERS cohort, 
respectively. Assuming that self-reported weight is an underes-
timate of the actual weight, this would overestimate any weight 
loss from baseline in the study, and dilute the eff ect of weight loss 
on loss or reduction of GERS, make the presented ORs closer to 
the null. In English,  “ heartburn ” and  “ regurgitation ” are known 
to be words that the general public not understands adequately. 
However, in Norwegian language, this is much less a problem. Th e 
Norwegian words  “ brystbrann ” / “ halsbrann ” and  “ sure oppst ø t ” 
used in this study are frequently used in the common language and 
are understood by the general public in the same way as healthcare 
professionals and researchers do. 
 Previous research on the eff ect of weight loss on GERS is lim-
ited, confl icting, and suff ers from varying defi nitions of GERD. 
Two randomized, double-blind, sham-controlled trials of gastric 
balloon distension on 42 and 28 extremely obese patients with pH-
verifi ed refl ux, but without grade C or D esophagitis (Los Angeles 
classifi cation ( 19 )) or large (  >  3  cm) hiatus hernia on endoscopy, 
found that weight loss was followed by reduced refl ux ( 20,21 ). 
An uncontrolled prospective study of 34 patients (mean BMI 
23.5  kg / m 2 ) with troublesome GERS, and either normal endoscopy 
or grade I esophagitis (Savary – Miller classifi cation ( 22 )), found 
improvement in refl ux symptom score aft er 6 weeks with a decrease 
of mean BMI of 1.7 units ( 23 ). Another uncontrolled prospective 
study of 18 volunteers (mean BMI 43.5  kg / m 2 ) with GERS found 
improvement in symptom score aft er a mean of 4 days with an 
average weight loss of 1.7  kg ( 24 ). In the Nurses ’ Health Study from 
the United States, there was a 36 % reduction in the risk of at least 
weekly GERS among women with at least a 3.5 decrease in BMI 
compared with those with no change in BMI (OR 0.64, 95 % CI 
0.42 – 0.97) ( 25 ). However, a randomized trial of 20 obese patients 
(mean BMI 31.4  kg / m 2 at inclusion) with pH-verifi ed refl ux, ero-
sive esophagitis, and daily GERS did not fi nd any eff ect on GERS 
with a mean decrease in BMI of 2.6 to 4.8 units ( 26 ). Th is study 
included participants with hiatus hernia, which contributes to the 
occurrence of GERD and is irreversible with weight loss. Th e only 
previous population-based study of the eff ect of weight change on 
GERS was from the United States and followed 637 individuals 
over a median of 10.5 years (mean age 62 years and 53 % females 
at follow-up) and found no relation between weight change and 
change in reported GERD symptoms ( 27 ). However, a major limi-
tation of that study was the use of self-reported height and weight. 
 Our results favor the hypothesis that weight loss improves 
GERS. Because of the observational design of the study, strict cau-
sality cannot be implied. However, the consistent and dose-related 
association between weight loss and reduction of GERS, which is 
preserved aft er adjustment for possible important confounders, 
argues for a valid conclusion. Th e data also indicate that even greater 
benefi ts might be seen in overweight individuals who achieve a 
larger weight loss. According to the Montreal defi nition and clas-
sifi cation,  “ GERD is a condition which develops when the refl ux of 
stomach contents causes troublesome symptoms and / or complica-
tions ” and it further states that  “ In population-based studies, mild 
symptoms occurring 2 or more days a week, or moderate / severe 
symptoms occurring more than 1 day a week, are oft en considered 
troublesome by patients ” ( 8 ). As the validation studies of our ques-
tionnaire showed that 95 – 98 % of the participants who reported 
severe GERS had at least weekly complaints, those reporting severe 
GERS in our study can be regarded as having GERD according to 
the Montreal defi nition. It seems that the weight loss needs to be 
substantial to improve severe GERS. Th is is probably because of 
the strong association between BMI and GERS. Even BMI in the 
upper normal range has been shown to be associated with GERS 
compared with BMI in the lower normal range ( 25 ). In addition, 
weight loss without regular use of antirefl ux medication does not 
seem to be suffi  cient. Th is probably refl ects an advanced stage of 
disease in these subjects, i.e., esophagitis or symptoms related to 
the presence of hiatal hernia, which does not resolve only with 
weight loss. However, weight loss was associated with an increased 
chance of treatment success with antirefl ux medication. 
 CONCLUSION 
In this large prospective population-based cohort study, weight 
loss was dose-dependently associated with reduction of GERS and 
increased chance of treatment success with antirefl ux medication. 
Th e study also suggests that patients with GERD using regular 
antirefl ux medication might benefi t from weight reduction. 
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 Figure 2 .  Adjusted odds ratio (OR) with 95 % conﬁ dence interval (95 % 
CI) for  reduction of severe gastroesophageal reﬂ ux symptoms (GERS) by 
change in body mass index (BMI) when using  at least weekly antireﬂ ux 
medication. 
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 Figure 3 .  Adjusted odds ratio (OR) with 95 % conﬁ dence interval (95 % CI) 
for  loss of severe gastroesophageal reﬂ ux symptoms (GERS) by change in 
body mass index (BMI) when using  at least weekly antireﬂ ux medication. 
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 Study Highlights 
 WHAT IS CURRENT KNOWLEDGE 
 3 The prevalence of gastroesophageal reﬂ ux symptoms 
(GERS) is high and increasing in Western populations. 
 3 High body mass index is a risk factor of GERS. 
 3 The effect of weight loss on GERS is not clear. 
 WHAT IS NEW HERE 
 3 Weight loss was associated with a reduction of GERS in the 
general population. 
 3 There was a dose-response relationship between weight loss 
and reduction of GERS. 
 3 Weight loss was associated with an increased treatment 
success with antireﬂ ux medication.  
 REFERENCES 
 1 .  Dent  J ,  El-Serag  HB ,  Wallander  MA  et al.  Epidemiology of gastro-oesopha-
geal refl ux disease: a systematic review .  Gut  2005 ; 54 : 710 – 7 . 
 2 .  Ness-Jensen  E ,  Lindam  A ,  Lagergren  J  et al.  Changes in prevalence, incidence 
and spontaneous loss of gastro-oesophageal refl ux symptoms: a prospective 
population-based cohort study, the HUNT study .  Gut  2012 ; 61 : 1390 – 7 . 
 3 .  Ronkainen  J ,  Aro  P ,  Storskrubb  T  et al.  Gastro-oesophageal refl ux symp-
toms and health-related quality of life in the adult general population--the 
Kalixanda study .  Aliment Pharmacol Th er  2006 ; 23 : 1725 – 33 . 

155 
 
Epidemiology of gastro-oesophageal reflux 
Paper III
 
 
 
 
nature publishing group ORIGINAL CONTRIBUTIONS
E
S
O
P
H
A
G
U
S
171
© 2014 by the American College of Gastroenterology The American Journal of GASTROENTEROLOGY
see related editorial on page x
 INTRODUCTION 
 Tobacco smoking is associated with an increased risk of gastro-
esophageal refl ux symptoms (GERS) according to several popula-
tion-based studies from Western countries ( 1 – 9 ). Th e odds ratios 
(ORs) of GERS among smokers compared with non-smokers 
have been in the range of 1.3 – 2.5. Tobacco smoking increases the 
risk of GERS by reducing the lower esophageal sphincter pres-
sure, facilitating gastric acid to reach the esophagus ( 10 – 12 ), 
and reducing the salivary bicarbonate secretion, which neu-
tralizes the acidity of the gastric contents ( 13,14 ). In addition, 
both GERS and tobacco smoking are independently associated 
with an increased risk of adenocarcinoma of the esophagus 
and esophagogastric junction ( 15 – 19 ). Two recent reviews 
on the eff ect of lifestyle changes on gastroesophageal refl ux 
disease (GERD) concluded that the evidence to date does not 
support an improvement in GERD aft er cessation of tobacco use 
( 20,21 ). However, in the available studies, only the very short-term 
eff ect of smoking cessation on GERD outcomes was evaluated 
( 22 – 24 ). Our hypothesis states that tobacco smoking cessation 
improves GERS. Th e aim of this study was to clarify if there is 
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an association between tobacco smoking cessation and improve-
ment in GERS in a large and population-based study with long 
follow-up. 
 METHODS 
 Study design, setting, and participants 
 Th e study was based on a large population-based health study, the 
Nord-Tr ø ndelag health study (the HUNT study), which we have 
used previously for epidemiological studies of GERS ( 6,25 – 27 ). 
Th e HUNT study is based on a series of health surveys where the 
entire population of Nord-Tr ø ndelag County, Norway, from 20 
years of age has been invited to participate. Th e fi rst survey was 
conducted in 1984 – 1986 (HUNT 1), the second survey in 1995 –
 1997 (HUNT 2), and the third survey in 2006 – 2008 (HUNT 3). In 
all surveys a basic questionnaire was accompanying the invitation 
letter and the participants were asked to meet at screening stations 
for clinical and laboratory examinations. A short questionnaire 
(Mini-Q) was sent to non-participants aft er HUNT 3 in 2009 
and those who responded to the Mini-Q were also included in 
our study. Th e questionnaires and examinations included a wide 
range of health-related topics ( 28 ). 
 Assessment of the outcome GERS 
 In HUNT 2 and HUNT 3 / Mini-Q, GERS status of the participants 
was defi ned based on the participants ’ response to the following 
question:  “ To what degree have you had heartburn or acid regur-
gitation during the previous 12 months? ” Th e question had three 
response alternatives:  “ No complaints, ”  “ Minor complaints, ” or 
 “ Severe complaints. ” Improvement in GERS status from severe 
GERS in HUNT 2 to no or minor GERS in HUNT 3 / Mini-Q 
was defi ned as the study outcome, whereas severe GERS at both 
time points (stable GERS) were defi ned as reference. We have 
previously validated this GERS question and found that 25 – 31 % 
of those reporting minor GERS and 95 – 98 % of those reporting 
severe GERS had at least weekly complaints ( 25 ). Th is suggests 
that the majority of those reporting severe GERS actually have 
GERD according to the Montreal defi nition and classifi cation of 
GERD ( 25,26,29 ). 
 Assessment of the exposure tobacco smoking 
 In HUNT 2, the participants were asked about their tobacco 
smoking status by answering yes or no to these questions:  “ Have 
you ever smoked daily?, ”  “ Do you smoke cigarettes daily?, ”  “ Do 
you smoke cigars or cigarillos daily?, ” and  “ Do you smoke pipe 
daily? ” In HUNT 3 / Mini-Q, the participants were asked:  “ Do you 
smoke? ” Th e response alternatives to this question were:  “ No, 
I have never smoked, ”  “ No, I have quit smoking, ”  “ Yes, cigarettes 
occasionally (parties / vacation, not daily), ” or  “ Yes, cigarettes 
daily. ” Th ose who quitted daily tobacco smoking or reduced 
daily smoking to only occasional smoking between HUNT 2 
and HUNT 3 / Mini-Q were defi ned as  “ exposed ” to tobacco 
smoking cessation, and those who were persistent daily tobacco 
smokers at both time points were regarded as  “ unexposed ” to 
such cessation. 
 Assessment of covariables 
 Covariables were selected based on their known association with 
GERS: sex, age, alcohol consumption, education, physical exer-
cise, body mass index (BMI), and antirefl ux medication. Data 
on sex and age at participation were recorded at each survey. 
Average frequency of alcohol consumption and physical exercise 
was reported through questionnaires in HUNT 3 / Mini-Q. Years 
of education were reported through questionnaires in HUNT 
2. BMI was assessed by objectively measuring height and body 
weight under standardized conditions and by trained personnel 
at the screening stations in HUNT 2 and HUNT 3, whereas in 
Mini-Q height and weight were reported by the responders. BMI 
was calculated as body weight in kilograms divided by the square 
height in meters (kg / m 2 ). Antirefl ux medication included proton 
pump inhibitors, histamine-2-receptor antagonists, and antacids. 
In Norway, the prescription rules have until 2010 demanded a 
prescription from a physician to get proton pump inhibitors or 
histamine-2-receptor antagonists, except small packages of low-
dose histamine-2-receptor antagonists that have been available 
over the counter. In this study, information was gathered on the 
participants ’ use of prescribed antirefl ux medication through the 
Norwegian Prescription Database (NorPD). Th e NorPD was estab-
lished in 2004, and all prescribed medications from all Norwegian 
pharmacies were by legislation reported to the NorPD. From the 
NorPD data, the average use of prescribed antirefl ux medication 
was estimated based on the number of tablets prescribed during 
the HUNT 3 data collection period (2006 – 2008). In addition, 
the questionnaires in HUNT 3 included an assessment of over 
the counter medication use against several complaints, including 
heartburn or acid regurgitation. Th e question was:  “ How oft en 
have you used over the counter medication against the following 
complaints during the last month? ” Th e participants responded 
with one of four alternatives to this question:  “ Rare / never, ”  “ 1 – 3 
times / week, ”  “ 4 – 6 times / week, ” or  “ Daily. ” Th us, the two data 
sources were complementary with regard to the use of antirefl ux 
medication. Th ere was no information on antirefl ux medication 
available during the HUNT 2 period. 
 Statistical analysis 
 Response rates were calculated from those eligible to participate 
at each survey, excluding those who were no longer residents in 
the county or had died. Th e association between tobacco smok-
ing cessation (exposure) and GERS status (outcome) was assessed 
by multivariable logistic regression. Based on acknowledged cri-
teria of a confounding factor, antirefl ux medication should not be 
included in the regression model, but instead be assessed as an 
eff ect modifi er ( 30 ). To account for the eff ect of antirefl ux medica-
tion on GERS, the analyses were stratifi ed by the use of antirefl ux 
medication, no or less than weekly use or at least weekly use, and 
the results were reported for each stratum separately. Participants 
with missing information on antirefl ux medication were analyzed 
as using no or less than weekly antirefl ux medication, because in 
the NorPD data it was not possible to distinguish between those 
with truly missing data and those who did not receive a pre-
scription. Secondary analyses were also stratifi ed by BMI using 
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the categories defi ned by the World Health Organization:   <  18.5 
(underweight), 18.5 – 24.9 (normal weight), 25.0 – 29.9 (preobese), 
and  ≥ 30.0 (obese) ( 31 ). To account for other potential confound-
ers of the association between tobacco smoking and GERS, a con-
tinuous variable for age and categorical variables for sex, alcohol 
consumption (  <  weekly or  ≥ weekly), education ( ≤ 12 years or   >  12 
years), and physical exercise (  <  weekly or  ≥ weekly) were included 
in the regression model. Th e statistical analyses were performed 
using Stata / IC 12.1 by StataCorp LP (College Station, TX). 
 Study approval 
 Th e study was approved by the Regional Committee for Medical 
and Health Research Ethics, Central-Norway (ID 4.2009.328). 
 RESULTS 
 Participants 
 We have previously published a complete fl owchart of the partici-
pants ( 26 ). In HUNT 2 and HUNT 3 / Mini-Q, 58,869 individuals 
(64 % response rate) and 44,997 individuals (49 % ) reported GERS 
status, respectively. Among these, the 29,610 individuals (61 % ) 
who reported GERS status at both time points were eligible. Th e 
average follow-up time was approximately 11 years. Among the 
1553 participants with severe GERS (5 % ) in HUNT 2, the 486 
(31 % ) who were daily tobacco smokers were included in the 
present study. Of these participants, 182 quitted smoking and 31 
reduced to occasional smoking. In total, 213 (44 % ) were previous 
daily smokers, whereas 251 (52 % ) were persistent daily smokers 
in HUNT 3 / Mini-Q. In both these groups, about 60 % were using 
antirefl ux medication at least weekly ( Figure 1 ). Th e mean BMI 
was similar between the groups, but obesity was less common 
among the persistent daily smokers. Compared with the previous 
daily smokers, the persistent daily smokers were characterized by 
higher female representation, lower mean age, lower education, 
lower level of physical exercise, and lower alcohol consumption 
( Table 1 ). 
 Associations 
 Among the daily tobacco smokers with severe GERS in HUNT 
2 using no or less than weekly antirefl ux medication, there was 
no statistically signifi cant association between tobacco smoking 
cessation and GERS status (adjusted OR 0.95; 95 % CI: 0.39 – 2.30) 
compared with persistent daily smoking ( Table 2 ). However, 
among the daily tobacco smokers with severe GERS in HUNT 
2 using at least weekly antirefl ux medication, tobacco smoking 
cessation was associated with an improvement in GERS status 
from severe to no or minor complaints (adjusted OR 1.78; 95 % 
CI: 1.07 – 2.97) compared with persistent daily smoking ( Table 2 ). 
Secondary, subgroup analyses found that the association only 
was present among individuals within the normal weight range 
Participants reporting GERS in both HUNT 2 and HUNT 3/Mini-Q
N=29,610
No or minor GERS in HUNT 2
n=28,057 (95%)
Severe GERS in HUNT 2
n=1,553 (5%)
Missing smoking status in HUNT 2
n=8 (1%)
Previous or never smokers in HUNT 2
n=1,059 (68%)
Daily smokers in HUNT 2
n=486 (31%)
Missing smoking status in HUNT 3/Mini-Q
n=22 (4%)
Previous daily smokers in HUNT 3/Mini-Q
n=213 (44%)
Persistent daily smokers in HUNT 3/Mini-Q
n=251 (52%)
No or < weekly
antireflux
medication in
HUNT 3/Mini-Q
n=86 (40%)
No or < weekly
antireflux
medication in
HUNT 3/Mini-Q
n=99 (39%)
   Weekly
antireflux
medication in
HUNT 3/Mini-Q
n=152 (61%)
Weekly
antireflux
medication in
HUNT 3/Mini-Q
n=127 (60%)
 Figure 1 .  Flow chart of study participants. GERS, gastroesophageal reﬂ ux symptoms; HUNT, Nord-Tr ø ndelag health study. 
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(adjusted OR 5.67; 95 % CI: 1.36 – 23.64), but not among over-
weight individuals ( Table 3 and  Figure 2 ). Th ere was no associa-
tion between tobacco smoking cessation and GERS status among 
individuals with minor GERS in HUNT 2 (data not shown). 
 DISCUSSION 
 Th is study found that tobacco smoking cessation was associated 
with an improvement in severe GERS among normal weight indi-
viduals using antirefl ux medication at least weekly. Th ere was, 
however, no such pattern in individuals with minor GERS, over-
weight, or those using antirefl ux medication less than weekly. 
 Strengths of this study include the population-based design, 
reducing selection bias, and increasing generalizability compared 
with clinic-based studies. Except for slightly lower average income 
and education and lack of a large city, the population of Nord-
Tr ø ndelag County is representative of the Norwegian population at 
large ( 28,32 ). In addition, the prospective design circumvents recall 
bias and the wide range of variables assessed, including antirefl ux 
medication, makes adjustments for relevant confounders possible. 
Limitations include the inherent arbitrary defi nition of GERD, 
reducing the accuracy of identifying individuals with true GERD, 
probably leading to some misclassifi cation. Misclassifi cation is 
also possible among the exposure and covariables, as the variables 
were dichotomized. In addition, the associations found were only 
modest and residual confounding can never be totally excluded in 
observational research. Loss to follow-up may introduce selection 
and survival bias, but such potential biases are probably small as 
 Table 1 .  Characteristics of study participants 
  Tobacco smoking status 
  Previous daily smokers ( n =213)  Persistent daily smokers ( n =251) 
 Antireﬂ ux medication  a   No or   <  weekly ( n =86)  ≥ Weekly ( n =127)  No or   <  weekly ( n =99)  ≥ Weekly ( n =152) 
 BMI  b 
  Mean (s.d.)  28.5 (4.7)  29.2 (4.5)  28.1 (5.0)  28.9 (5.1) 
  Median (range)  28.1 (18.7 – 47.2)  29.0 (19.0 – 44.1)  27.8 (18.9 – 49.3)   28.0 (15.2 – 47.5) 
   <  18.5, no. ( % )  0 (0.0)  0 (0.0)  0 (0.0)  2 (1.3) 
  18.5 – 24.9, no. ( % )  22 (25.6)  20 (15.7)  28 (28.3)   30 (19.7) 
  25.0 – 29.9, no. ( % )  35 (40.7)  55 (43.3)  42 (42.4)   69 (45.4) 
  ≥ 30.0, no. ( % )  29 (33.7)  49 (38.6)  28 (28.3)   51 (33.6) 
  Missing, no. ( % )  0 (0.0)  3 (2.4)  1 (1.0)  0 (0.0) 
 Sex, no. ( % ) 
  Women  37 (43)  54 (43)  52 (53)  92 (61) 
 Age (years) 
  Mean (s.d.)  55.7 (11.7)  58.9 (9.9)  51.8 (10.3)  57.5 (10.3) 
  Median (range)  55.3 (32.8 – 84.9)  58.6 (34.3 – 84.7)  51.3 (34.1 – 84.4)   56.7 (31.9 – 87.8) 
 Alcohol consumption, no. ( % ) 
   <  Weekly  51 (59.3)  82 (64.6)  65 (65.7)  107 (70.4) 
  ≥ Weekly  34 (39.5)  44 (34.6)  34 (34.3)  44 (28.9) 
  Missing  1 (1.2)  1 (0.8)  0 (0.0)  1 (0.7) 
 Education, no. ( % ) 
  ≤ 12 years  67 (77.9)  112 (88.2)  91 (91.9)  135 (88.8) 
   >  12 years  17 (19.8)  13 (10.2)  7 (7.1)  14 (9.2) 
  Missing  2 (2.3)  2 (1.6)  1 (1.0)  3 (2.0) 
 Physical exercise, no. ( % ) 
   <  Weekly  28 (32.6)  33 (26.0)  38 (38.4)  56 (36.8) 
  ≥  Weekly  58 (67.4)  92 (72.4)  61 (61.6)  94 (61.8) 
  Missing  0 (0.0)  2 (1.6)  0 (0.0)  2 (1.3) 
 Participants with no information on antireﬂ ux medication were included in never or less than weekly category. 
 a Antireﬂ ux medication: proton pump inhibitors, histamine-2-receptor antagonists, and antacids; participants with no information on antireﬂ ux medication were included in 
never or  < weekly category. 
 b BMI: body mass index (kg / m 2 ). 
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the general population. As this is an observational study, a causal 
relationship cannot be claimed, and we do not know if smok-
ing cessation occurred before improvement of GERS or the other 
way around. However, the results are consistent with the patho-
physiology ( 10 – 14 ) and a randomized controlled trial of smok-
ing cessation would be very hard and unethical to perform. Th e 
study only considered frequency of tobacco smoking, not dose 
or time since cessation. However, pathophysiologic data sug-
gests that the eff ect of tobacco smoking is very short lived, and 
thus dose and time since cessation should be of less importance. 
In addition, daily smoking is a common cutoff  level in observa-
tional study, making comparisons with other studies easier. We 
found no association between tobacco smoking cessation and 
improvement in minor GERS. Th is probably refl ects the hetero-
genetic nature of individuals reporting minor GERS, including 
individuals with functional syndromes. Th ese syndromes have 
other pathophysiological mechanisms, at least partly not related 
to gastroesophageal refl ux or tobacco smoking. Owing to the 
low absolute number of individuals, we defi ned the  “ exposure ” 
in this study to be a combination of those quitting smoking and 
those only reducing daily smoking to occasional smoking. Even 
so, we found an association between the  “ exposure, ” i.e., reduced 
a previous publication has shown that there was virtually no dif-
ference in the distribution of the study variables between all the 
HUNT 2 participants ( N  =  58,869) and the cohort who was fol-
lowed up from HUNT 2 to HUNT 3 / Mini-Q ( N  =  29,610) ( 27 ). 
Owing to the observational design, causal relationships cannot be 
claimed. As there were low numbers of missing data among the 
participants ( Table 1 ), complete case analyses were performed. 
 Th e three previous studies addressing smoking cessation and 
GERD found confl icting results. One study found no infl uence 
of 24  h refrainment from smoking on 24-h pH measurements 
of the distal esophagus in 10 smokers with GERS ( 22 ). Another 
study found no immediate eff ect of smoking cessation on total 
esophageal acid exposure in eight smoking men with moderate-
to-severe endoscopic evidence of GERD ( 23 ). Th e third study, 
however, found a reduced distal esophageal acid exposure in 14 
smokers with refl ux esophagitis who abstained from smoking 
for 48  h ( 24 ). Our study is the fi rst epidemiological investigation 
testing whether tobacco smoking cessation improves GERS and 
the fi rst study that evaluates such cessation in a long-term per-
spective. 
 Th e results of our study suggest that tobacco smoking cessation 
may improve severe GERS among normal weight individuals in 
 Table 2 .  OR with 95 % CI of improvement in severe GERS by tobacco smoking cessation, stratiﬁ ed by use of antireﬂ ux medication a 
  Unadjusted  Adjusted for sex and age  Fully adjusted b 
 Antireﬂ ux medication c  No.  OR  95 % CI  No.  OR  95 % CI  No.  OR  95 % CI 
 No or   <  weekly  185  1.12  0.48 – 2.62  185  1.06  0.45 – 2.52  181  0.95  0.39 – 2.30 
 ≥  Weekly  279  1.44  0.90 – 2.32  279  1.62  0.99 – 2.65  268  1.78  1.07 – 2.97 
 CI, conﬁ dence interval; GERS, gastroesophageal reﬂ ux symptoms; HUNT, Nord-Tr ø ndelag health study; OR, odds ratio. 
 Comparing previous daily smokers with persistent daily smokers as reference. 
 a From severe heartburn or acid regurgitation (GERS) in HUNT 2, to no or minor GERS in HUNT 3/Mini-Q; comparing previous daily smokers with persistent daily smokers 
as reference. 
 b Adjusted for sex, age, body mass index, alcohol consumption, years of education, and physical exercise. 
 c Antireﬂ ux medication: proton pump inhibitors, histamine-2-receptor antagonists, and antacids. 
 Table 3 .  OR with 95 % CI of improvement in severe GERS by tobacco smoking cessation, stratiﬁ ed by the use of antireﬂ ux medication and BMI a 
   Unadjusted  Adjusted for sex and age  Fully adjusted b 
 Antireﬂ ux medication c  BMI (kg / m  2  )  No.  OR  95 % CI  No.  OR  95 % CI  No.  OR  95 % CI 
 No or   <  weekly  All  185  1.12  0.48 – 2.62  185  1.06  0.45 – 2.52  181  0.95  0.39 – 2.30 
  18.5 – 24.9  50  1.06  0.21 – 5.30  50  0.89  0.17 – 4.65  49  0.80  0.13 – 5.08 
  25.0 – 29.9  77  1.29  0.33 – 5.00  77  1.32  0.33 – 5.27  63  1.13  0.27 – 4.75 
  ≥  30.0  57  1.04  0.23 – 4.64  57  0.74  0.14 – 3.89  57  0.90  0.16 – 5.17 
 ≥ Weekly  All  279  1.44  0.90 – 2.32  279  1.62  0.99 – 2.65  268  1.78  1.07 – 2.97 
  18.5 – 24.9  50  3.92  1.13 – 13.60  50  4.70  1.22 – 18.18  49  5.67  1.36 – 23.64 
  25.0 – 29.9  124  1.25  0.62 – 2.56  124  1.20  0.57 – 2.53  121  1.24  0.57 – 2.71 
  ≥  30.0  100  1.01  0.46 – 2.22  100  1.28  0.55 – 2.99  93  1.29  0.53 – 3.17 
 BMI, body mass index; CI, conﬁ dence interval; GERS, gastroesophageal reﬂ ux symptoms; HUNT, Nord-Tr ø ndelag health study; OR, odds ratio. 
 a From severe heartburn or acid regurgitation (GERS) in HUNT 2, to no or minor GERS in HUNT 3/Mini-Q; comparing previous daily smokers with persistent daily smokers 
as reference. 
 b Adjusted for sex, age, body mass index, alcohol consumption, years of education, and physical exercise. 
 c Antireﬂ ux medication: proton pump inhibitors, histamine-2-receptor antagonists, and antacids. 
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tobacco smoking, and the outcome, i.e., improved GERS. Th is 
suggests that total smoking cessation would increase the chance 
of success even more than apparent from our study. Th e improve-
ment in GERS was limited to persons of normal weight using at 
least weekly antirefl ux medication. Th e lack of improvement in 
overweight individuals might be explained by the strong associa-
tion between BMI and GERS, which might dominate compared 
with the eff ect of tobacco smoking on GERS in overweight indi-
viduals. Th us, the pathophysiology of GERS is probably driven 
by the weight in overweight and obese individuals and smoking 
has a minor role, but in individuals of normal weight smoking 
has a more important role in the pathophysiology. Th e lack of 
improvement among those using no or less than weekly antire-
fl ux medication suggests that the individuals with severe GERS 
have an advanced stage of GERD, i.e., esophagitis or symptoms 
related to the presence of hiatal hernia, which does not resolve 
only with tobacco smoking cessation. However, weight loss and 
tobacco smoking cessation might reduce the need for antirefl ux 
medication over time. In addition, these lifestyle measures are 
also advisable owing to the eff ects on general health. As tobacco 
smoking as well as GERS is associated with adenocarcinoma 
of the distal esophagus and gastric cardia, persons with GERS 
should be advised to refrain from smoking ( 16 – 19 ). Th e popu-
lation-based design argues for generalizability to the general 
Norwegian population and other Western populations of mainly 
Caucasians. 
 In conclusion, although tobacco smoking cessation was not 
associated with any decrease in GERS among individuals with 
minor GERS, overweight, or those using antireflux medication 
less than weekly, an improvement in severe GERS was identi-
fied among normal weight individuals using regular antireflux 
medication. Tobacco smoking cessation might be beneficial in 
this latter group of patients suffering from gastroesophageal 
reflux. 
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 Study Highlights 
 WHAT IS CURRENT KNOWLEDGE 
 3 Gastroesophageal reﬂ ux symptoms (GERS) are prevalent in 
Western populations and associated with reduced health-
related quality of life and increased risk of esophageal 
adenocarcinoma. 
 3 Tobacco smoking is associated with an increased the risk of 
GERS. 
 3 The effect of tobacco smoking cessation on GERS is not 
clear. 
 WHAT IS NEW HERE 
 3 This study did not ﬁ nd any association between tobacco 
smoking cessation and improvement in GERS in individuals 
not using regular antireﬂ ux medication. 
 3 Tobacco smoking cessation was associated with an improve-
ment in severe GERS in individuals of normal weight using 
regular antireﬂ ux medication. 
 3 Tobacco smoking cessation was associated with an in-
creased chance of treatment success with regular use of 
antireﬂ ux medication in severe GERS. 
 3 This study suggests that tobacco smoking cessation might 
be beneﬁ cial in normal weight patients suffering from 
gastroesophageal reﬂ ux. 
30.0
25.0–29.9
0.1 0.5
Odds ratio (95% Cl)
1 5.0 10 30
BM
I (k
g/m
2 ) 18.5–24.9
All
 Figure 2 .  Odds ratio and 95 % conﬁ dence interval (CI) of improvement in 
severe gastroesophageal reﬂ ux symptoms by tobacco smoking cessation, 
comparing previous daily tobacco smokers with persistent daily tobacco 
smokers as reference. Restricted to those using  at least weekly antireﬂ ux 
medication and stratiﬁ ed by body mass index (BMI). Model adjusted for 
sex, age, alcohol consumption, education, and physical exercise. 
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